1
|
Goldberg I, Granot G, Telerman A, Partouche S, Shochat T, Halperin E, Gafter-Gvili A, Shargian L, Yeshurun M, Raanani P, Wolach O, Yahalom V. Extracorporeal photopheresis induces NETosis in neutrophils derived from patients with chronic graft-vs-host disease. J Clin Apher 2023; 38:615-621. [PMID: 37439388 DOI: 10.1002/jca.22073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2022] [Revised: 05/25/2023] [Accepted: 06/26/2023] [Indexed: 07/14/2023]
Abstract
INTRODUCTION Extracorporeal photopheresis (ECP) is considered an effective treatment for patients with chronic graft vs host disease (cGVHD) and demonstrates efficacy in ameliorating GVHD. The mechanism by which ECP acts against cGVHD is not fully understood. Preliminary observations have hinted at the potential involvement of neutrophil extracellular traps (NETs) formation in the pathogenesis of cGVHD. We aimed to assess the influence of ECP on the formation of NETs in patients with cGVHD as a potential mechanism in this setting. METHODS Patients treated with ECP for cGVHD at the Rabin Medical Center were included in this study. Blood samples were obtained at three different time points: before starting an ECP cycle, at the end of the first day of treatment, and 24 h following the initiation of the ECP treatment cycle. Neutrophils were harvested from all blood samples. NET formation was assessed by measurement of NET-bound specific neutrophil elastase activity and by immunofluorescence staining. RESULTS Six patients (two females and four males) with cGVHD were included in the study. We observed a significant increase in NET formation among all six patients following ECP. Net-bound specific neutrophil elastase activity was elevated from a median value of 2.23 mU/mL (interquartile range [IQR] 2.06-2.47 mU/mL) at baseline to a median value of 13.06 mU/mL (IQR 10.27-15.97 mU/mL) immediately after the treatment and to a peak median value of 14.73 mU/mL (IQR 9.6-22.38 mU/mL) 24 h following the initiation of the ECP cycle. A qualitative assessment of NET formation using immunofluorescence staining has demonstrated markedly increased expression of citrullinated histone H3, a marker of NET formation, following ECP treatment. CONCLUSIONS Our preliminary data indicate that ECP induces NET formation among patients with cGVHD. The contribution of increased NET formation to the therapeutic effect of cGVHD should be further investigated.
Collapse
Affiliation(s)
- Idan Goldberg
- Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
- Sackler School Medicine, Tel Aviv University, Tel Aviv, Israel
- Department of Internal Medicine F - Recanati, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
| | - Galit Granot
- Felsenstein Medical Research Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
| | - Alona Telerman
- Felsenstein Medical Research Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
| | - Shirly Partouche
- Felsenstein Medical Research Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
| | - Tzippy Shochat
- Statistical Consulting Unit, Beilinson Hospital, Rabin Medical Centre, Petah Tikva, Israel
| | - Erez Halperin
- Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
| | - Anat Gafter-Gvili
- Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
- Sackler School Medicine, Tel Aviv University, Tel Aviv, Israel
- Department of Internal Medicine A, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
| | - Liat Shargian
- Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
- Sackler School Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Moshe Yeshurun
- Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
- Sackler School Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Pia Raanani
- Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
- Sackler School Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Ofir Wolach
- Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
- Sackler School Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Vered Yahalom
- Sackler School Medicine, Tel Aviv University, Tel Aviv, Israel
- Blood Services & Apheresis Institute, Rabin Medical Center, Petah Tikva, Israel
| |
Collapse
|
2
|
Yahalom V, Miller L. An overview of apheresis activities in Israel 2022. Transfus Apher Sci 2023; 62:103793. [PMID: 37661488 DOI: 10.1016/j.transci.2023.103793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/05/2023]
Affiliation(s)
- Vered Yahalom
- Blood Services and Apheresis Institute, Rabin Medical Center, School of Medicine Tel Aviv University, Petah Tiqva, Israel; Israeli Transfusion Medicine Working Group (ITMWG), Israel.
| | - Liron Miller
- Blood Bank and Coagulation Laboratory Director, Sheba Medical Center, Ramat Gan, Israel; ITMWG, Israel
| |
Collapse
|
3
|
Adler O, Zait Y, Cohen N, Blazquez R, Doron H, Monteran L, Scharff Y, Shami T, Mundhe D, Glehr G, Kanner AA, Horn S, Yahalom V, Haferkamp S, Hutchinson JA, Bleckmann A, Nahary L, Benhar I, Yust Katz S, Pukrop T, Erez N. Reciprocal interactions between innate immune cells and astrocytes facilitate neuroinflammation and brain metastasis via lipocalin-2. Nat Cancer 2023; 4:401-418. [PMID: 36797502 DOI: 10.1038/s43018-023-00519-w] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Accepted: 01/17/2023] [Indexed: 04/19/2023]
Abstract
Brain metastasis still encompass very grim prognosis and therefore understanding the underlying mechanisms is an urgent need toward developing better therapeutic strategies. We uncover the intricate interactions between recruited innate immune cells and resident astrocytes in the brain metastatic niche that facilitate metastasis of melanoma and breast cancer. We show that granulocyte-derived lipocalin-2 (LCN2) induces inflammatory activation of astrocytes, leading to myeloid cell recruitment to the brain. LCN2 is central to inducing neuroinflammation as its genetic targeting or bone-marrow transplantation from LCN2-/- mice was sufficient to attenuate neuroinflammation and inhibit brain metastasis. Moreover, high LCN2 levels in patient blood and brain metastases in multiple cancer types were strongly associated with disease progression and poor survival. Our findings uncover a previously unknown mechanism, establishing a central role for the reciprocal interactions between granulocytes and astrocytes in promoting brain metastasis and implicate LCN2 as a prognostic marker and potential therapeutic target.
Collapse
Affiliation(s)
- Omer Adler
- Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Yael Zait
- Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Noam Cohen
- Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Raquel Blazquez
- Department of Internal Medicine III, Hematology and Medical Oncology, University Hospital Regensburg, Regensburg, Germany
| | - Hila Doron
- Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Lea Monteran
- Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Yeela Scharff
- Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Tamar Shami
- Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Dhanashree Mundhe
- Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Gunther Glehr
- Department of Surgery, University Hospital Regensburg, Regensburg, Germany
| | - Andrew A Kanner
- Department of Neurosurgery, Rabin Medical Center and Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel
| | - Suzana Horn
- Department of Pathology, Rabin Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Vered Yahalom
- Blood Services & Apheresis Institute, Rabin Medical Center and Tel Aviv University, Tel Aviv, Israel
| | - Sebastian Haferkamp
- Department of Dermatology, University Hospital Regensburg, Regensburg, Germany
| | - James A Hutchinson
- Department of Surgery, University Hospital Regensburg, Regensburg, Germany
| | - Annalen Bleckmann
- Department of Hematology/Medical Oncology, University Medical Center Göttingen, Göttingen, Germany
- Medical Clinic A, Haematology, Haemostasiology, Oncology and Pulmonology, University Hospital Münster, Münster, Germany
- West German Cancer Center, University Hospital Münster, Münster, Germany
| | - Limor Nahary
- The Shmunis School of Biomedicine and Cancer Research, the George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
| | - Itai Benhar
- The Shmunis School of Biomedicine and Cancer Research, the George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
| | - Shlomit Yust Katz
- Neuro-Oncology Unit, Davidoff Cancer Center at Rabin Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Tobias Pukrop
- Department of Internal Medicine III, Hematology and Medical Oncology, University Hospital Regensburg, Regensburg, Germany
- Division of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany
| | - Neta Erez
- Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
| |
Collapse
|
4
|
Yeshurun M, Yahalom V, Goldman-Levi R, Golomb N, Livny E, Mimouni M, Rubinstein M, Raanani P, Shargian L, Nahum Y. Allogeneic Fresh Frozen Plasma for the Treatment of Ocular Graft-Versus-Host-Disease: Prospective Phase 2 Open-Label Study. Transplant Cell Ther 2023. [DOI: 10.1016/s2666-6367(23)00406-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
5
|
Safra M, Tamari Z, Polak P, Shiber S, Matan M, Karameh H, Helviz Y, Levy-Barda A, Yahalom V, Peretz A, Ben-Chetrit E, Brenner B, Tuller T, Gal-Tanamy M, Yaari G. Altered somatic hypermutation patterns in COVID-19 patients classifies disease severity. Front Immunol 2023; 14:1031914. [PMID: 37153628 PMCID: PMC10154551 DOI: 10.3389/fimmu.2023.1031914] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Accepted: 03/22/2023] [Indexed: 05/10/2023] Open
Abstract
Introduction The success of the human body in fighting SARS-CoV2 infection relies on lymphocytes and their antigen receptors. Identifying and characterizing clinically relevant receptors is of utmost importance. Methods We report here the application of a machine learning approach, utilizing B cell receptor repertoire sequencing data from severely and mildly infected individuals with SARS-CoV2 compared with uninfected controls. Results In contrast to previous studies, our approach successfully stratifies non-infected from infected individuals, as well as disease level of severity. The features that drive this classification are based on somatic hypermutation patterns, and point to alterations in the somatic hypermutation process in COVID-19 patients. Discussion These features may be used to build and adapt therapeutic strategies to COVID-19, in particular to quantitatively assess potential diagnostic and therapeutic antibodies. These results constitute a proof of concept for future epidemiological challenges.
Collapse
Affiliation(s)
- Modi Safra
- Bio-engineering, Faculty of Engineering, Bar Ilan University, Ramat Gan, Israel
- Bar Ilan Institute of Nanotechnologies and Advanced Materials, Bar Ilan University, Ramat Gan, Israel
| | - Zvi Tamari
- Bio-engineering, Faculty of Engineering, Bar Ilan University, Ramat Gan, Israel
- Bar Ilan Institute of Nanotechnologies and Advanced Materials, Bar Ilan University, Ramat Gan, Israel
| | - Pazit Polak
- Bio-engineering, Faculty of Engineering, Bar Ilan University, Ramat Gan, Israel
- Bar Ilan Institute of Nanotechnologies and Advanced Materials, Bar Ilan University, Ramat Gan, Israel
| | - Shachaf Shiber
- Emergency Department, Rabin Medical Center-Belinson Campus, Petah Tikva, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Moshe Matan
- Clinical Microbiology Laboratory, Baruch Padeh Medical Center, Poriya, Israel
| | - Hani Karameh
- Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Hebrew University School of Medicine, Jerusalem, Israel
| | - Yigal Helviz
- Intensive Care Unit, Shaare Zedek Medical Center, Hebrew University School of Medicine, Jerusalem, Israel
| | - Adva Levy-Barda
- Biobank, Department of Pathology, Rabin Medical Center-Belinson Campus, Petah Tikva, Israel
| | - Vered Yahalom
- Blood Services and Apheresis Institute, Rabin Medical Center, Petah Tikva, Israel
| | - Avi Peretz
- Clinical Microbiology Laboratory, Baruch Padeh Medical Center, Poriya, Israel
- The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel
| | - Eli Ben-Chetrit
- Infectious Diseases Unit, Shaare Zedek Medical Center, Hebrew University School of Medicine, Jerusalem, Israel
| | - Baruch Brenner
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- Institute of Oncology, Rabin Medical Center-Belinson Campus, Petah Tikva, Israel
| | - Tamir Tuller
- Department of Biomedical Engineering and The Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel
| | | | - Gur Yaari
- Bio-engineering, Faculty of Engineering, Bar Ilan University, Ramat Gan, Israel
- Bar Ilan Institute of Nanotechnologies and Advanced Materials, Bar Ilan University, Ramat Gan, Israel
- *Correspondence: Gur Yaari,
| |
Collapse
|
6
|
Gassner C, Castilho L, Chen Q, Clausen FB, Denomme GA, Flegel WA, Gleadall N, Hellberg Å, Ji Y, Keller MA, Lane WJ, Ligthart P, Lomas-Francis C, Nogues N, Olsson ML, Peyrard T, Storry JR, Tani Y, Thornton N, van der Schoot E, Veldhuisen B, Wagner F, Weinstock C, Wendel S, Westhoff C, Yahalom V, Hyland CA. International Society of Blood Transfusion Working Party on Red Cell Immunogenetics and Blood Group Terminology Report of Basel and three virtual business meetings: Update on blood group systems. Vox Sang 2022; 117:1332-1344. [PMID: 36121188 PMCID: PMC10680040 DOI: 10.1111/vox.13361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2022] [Revised: 08/30/2022] [Accepted: 08/31/2022] [Indexed: 11/27/2022]
Abstract
BACKGROUND AND OBJECTIVES Under the ISBT, the Working Party (WP) for Red Cell Immunogenetics and Blood Group Terminology is charged with ratifying blood group systems, antigens and alleles. This report presents the outcomes from four WP business meetings, one located in Basel in 2019 and three held as virtual meetings during the COVID-19 pandemic in 2020 and 2021. MATERIALS AND METHODS As in previous meetings, matters pertaining to blood group antigen nomenclature were discussed. New blood group systems and antigens were approved and named according to the serologic, genetic, biochemical and cell biological evidence presented. RESULTS Seven new blood group systems, KANNO (defined numerically as ISBT 037), SID (038), CTL2 (039), PEL (040), MAM (041), EMM (042) and ABCC1 (043) were ratified. Two (039 and 043) were de novo discoveries, and the remainder comprised reported antigens where the causal genes were previously unknown. A further 15 blood group antigens were added to the existing blood group systems: MNS (002), RH (004), LU (005), DI (010), SC (013), GE (020), KN (022), JMH (026) and RHAG (030). CONCLUSION The ISBT now recognizes 378 antigens, of which 345 are clustered within 43 blood group systems while 33 still have an unknown genetic basis. The ongoing discovery of new blood group systems and antigens underscores the diverse and complex biology of the red cell membrane. The WP continues to update the blood group antigen tables and the allele nomenclature tables. These can be found on the ISBT website (http://www.isbtweb.org/working-parties/red-cell-immunogenetics-and-blood-group-terminology/).
Collapse
Affiliation(s)
- Christoph Gassner
- Institute of Translational Medicine, Private University in the Principality of Liechtenstein, Triesen, Liechtenstein
| | | | - Qing Chen
- Jiangsu Province Blood Center, Nanjing, Jiangsu, China
| | - Frederik Banch Clausen
- Department of Clinical Immunology, Laboratory of Blood Genetics, Copenhagen University Hospital, Copenhagen, Denmark
| | | | - Willy A. Flegel
- Department of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
| | - Nick Gleadall
- Department of Haematology, University of Cambridge and NHS Blood and Transplant, Cambridge Biomedical Campus, Cambridge, UK
| | - Åsa Hellberg
- Department of Clinical Immunology and Transfusion Medicine, Office for Medical Services, Region Skåne, Sweden
| | - Yanli Ji
- Institute of Clinical Blood Transfusion, Guangzhou Blood Center, Guangzhou, People’s Republic of China
| | | | - William J. Lane
- Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Peter Ligthart
- Department of Diagnostic Immunohematology, Sanquin, Amsterdam, The Netherlands
| | - Christine Lomas-Francis
- Laboratory of Immunohematology and Genomics, New York Blood Center Enterprise, New York, New York, USA
| | | | - Martin L. Olsson
- Department of Clinical Immunology and Transfusion Medicine, Office for Medical Services, Region Skåne, Sweden
- Department of Laboratory Medicine, Division of Hematology and Transfusion Medicine, Lund University, Lund, Sweden
| | - Thierry Peyrard
- Etablissement Français du Sang Ile-de-France, Centre National de Référence pour les Groupes sanguins, Ivry-sur-Seine, France
- UMR_S1134 Inserm Université Paris Cité, Paris, France
| | - Jill R. Storry
- Department of Clinical Immunology and Transfusion Medicine, Office for Medical Services, Region Skåne, Sweden
- Department of Laboratory Medicine, Division of Hematology and Transfusion Medicine, Lund University, Lund, Sweden
| | | | - Nicole Thornton
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK
| | - Ellen van der Schoot
- Department of Experimental Immunohematology, Sanquin, Amsterdam, The Netherlands
| | - Barbera Veldhuisen
- Department of Diagnostic Immunohematology, Sanquin, Amsterdam, The Netherlands
- Department of Experimental Immunohematology, Sanquin, Amsterdam, The Netherlands
| | - Franz Wagner
- German Red Cross Blood Service NSTOB, Springe, Germany
- MVZ Clementinenkrankenhaus, Springe, Germany
| | - Christof Weinstock
- Department of Transfusion Medicine, Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Service, Ulm, Germany
| | | | - Connie Westhoff
- Laboratory of Immunohematology and Genomics, New York Blood Center Enterprise, New York, New York, USA
| | - Vered Yahalom
- Rabin Medical Center, Petach Tiqva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | | |
Collapse
|
7
|
Perl L, Cohen A, Dadashev A, Shapira Y, Vaknin-Assa H, Yahalom V, Sagie A, Kornowski R, Hirsch R. Long-term outcomes of catheter-based intervention for clinically significant paravalvular leak. EUROINTERVENTION 2021; 17:736-743. [PMID: 33720018 PMCID: PMC9725040 DOI: 10.4244/eij-d-20-01206] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
BACKGROUND In most centres, clinically significant percutaneous paravalvular leak (PVL) closure following valve replacement surgery is reserved for those considered high-risk for surgery. There is a paucity of data regarding the long-term outcomes of these patients. AIMS Our goals were to assess the long-term outcomes of patients undergoing percutaneous PVL closure. METHODS A total of 100 consecutive transcatheter PVL closure procedures (74 mitral, 26 aortic) were performed in 95 patients between February 2005 and August 2019 at our hospital. Data collected included procedural success rates, indication-specific outcomes and mortality. RESULTS Mean follow-up was 5.6±6.1 years, mean age 62.6±15.2 years, and 45.4% were female. The device was successfully implanted in 88 procedures (88.0%). Patients who presented with heart failure (n=57) had a significant improvement in NYHA classification (29.2% Class III/IV versus 100.0%, p<0.001). For patients who presented with haemolytic anaemia (n=38), haemoglobin increased (11.94±1.634 vs 9.72±1.49, p<0.001) and LDH levels were reduced (1,354.90±1,225.55 vs 2,039.40±1,347.20, p<0.001) following the procedure. Rates of mortality were 3.8% at 90 days, 15.6% after 1 year, and 27.2% after 5 years. CONCLUSIONS For patients who are deemed intermediate- to high-risk for repeat surgery, transcatheter PVL closure shows reasonable clinical success rates, with a significant improvement in symptoms, and a relatively low rate of periprocedural complications.
Collapse
Affiliation(s)
- Leor Perl
- Department of Cardiology, Rabin Medical Center, Beilinson Hospital, 39 Jabotinsky St, Petach Tikva, 4941492, Israel
| | - Amir Cohen
- Cardiology Department, Rabin Medical Center and “Sackler” School of Medicine, Tel Aviv University, Petach Tikva, Israel
| | - Alexander Dadashev
- Cardiology Department, Rabin Medical Center and “Sackler” School of Medicine, Tel Aviv University, Petach Tikva, Israel
| | - Yaron Shapira
- Cardiology Department, Rabin Medical Center and “Sackler” School of Medicine, Tel Aviv University, Petach Tikva, Israel
| | - Hana Vaknin-Assa
- Cardiology Department, Rabin Medical Center and “Sackler” School of Medicine, Tel Aviv University, Petach Tikva, Israel
| | - Vered Yahalom
- Blood Services & Apheresis Institute, Rabin Medical Center and “Sackler” School of Medicine, Tel Aviv University, Petach Tikva, Israel
| | - Alexander Sagie
- Cardiology Department, Rabin Medical Center and “Sackler” School of Medicine, Tel Aviv University, Petach Tikva, Israel
| | - Ran Kornowski
- Cardiology Department, Rabin Medical Center and “Sackler” School of Medicine, Tel Aviv University, Petach Tikva, Israel
| | - Rafael Hirsch
- Cardiology Department, Rabin Medical Center and “Sackler” School of Medicine, Tel Aviv University, Petach Tikva, Israel
| |
Collapse
|
8
|
Asher O, Finkel L, Yosephi L, Karamatic Crew V, Thornton N, Chezar J, Akria L, Shinar E, Yahalom V. CROK (CROM19): A new high-prevalence antigen in the Cromer blood group system. Transfusion 2021; 61:E85-E87. [PMID: 34558678 DOI: 10.1111/trf.16680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2021] [Revised: 08/09/2021] [Accepted: 09/04/2021] [Indexed: 11/29/2022]
Affiliation(s)
- Orna Asher
- National Blood Group Reference Laboratory (NBGRL), Magen David Adom (MDA), National Blood Services, Ramat Gan, Israel
| | - Lilach Finkel
- National Blood Group Reference Laboratory (NBGRL), Magen David Adom (MDA), National Blood Services, Ramat Gan, Israel
| | - Lydia Yosephi
- National Blood Group Reference Laboratory (NBGRL), Magen David Adom (MDA), National Blood Services, Ramat Gan, Israel
| | | | - Nicole Thornton
- International Blood Group Reference Laboratory (IBGRL), NHSBT, Bristol, UK
| | - Judith Chezar
- Blood Bank, The Western Galilee Hospital, Nahariya, Israel.,Bar-Ilan University, Azrieli Faculty of Medicine, Safed, Israel
| | - Luiza Akria
- Blood Bank, The Western Galilee Hospital, Nahariya, Israel.,Bar-Ilan University, Azrieli Faculty of Medicine, Safed, Israel
| | - Eilat Shinar
- National Blood Group Reference Laboratory (NBGRL), Magen David Adom (MDA), National Blood Services, Ramat Gan, Israel.,Faculty of Health Sciences, Ben Gurion University, Beersheba, Israel
| | - Vered Yahalom
- National Blood Group Reference Laboratory (NBGRL), Magen David Adom (MDA), National Blood Services, Ramat Gan, Israel.,Blood Services & Apheresis Institute, Rabin Medical Center, Petah Tiqva, Israel.,Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
9
|
Cohen S, Partouche S, Gurevich M, Tennak V, Mezhybovsky V, Azarov D, Soffer-Hirschberg S, Hovav B, Niv-Drori H, Weiss C, Borovich A, Cohen G, Wertheimer A, Shukrun G, Israeli M, Yahalom V, Leshem-Lev D, Perl L, Kornowski R, Wiznitzer A, Tobar A, Feinmesser M, Mor E, Atar E, Nesher E. Generation of vascular chimerism within donor organs. Sci Rep 2021; 11:13437. [PMID: 34183759 PMCID: PMC8238957 DOI: 10.1038/s41598-021-92823-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Accepted: 06/16/2021] [Indexed: 01/22/2023] Open
Abstract
Whole organ perfusion decellularization has been proposed as a promising method to generate non-immunogenic organs from allogeneic and xenogeneic donors. However, the ability to recellularize organ scaffolds with multiple patient-specific cells in a spatially controlled manner remains challenging. Here, we propose that replacing donor endothelial cells alone, while keeping the rest of the organ viable and functional, is more technically feasible, and may offer a significant shortcut in the efforts to engineer transplantable organs. Vascular decellularization was achieved ex vivo, under controlled machine perfusion conditions, in various rat and porcine organs, including the kidneys, liver, lungs, heart, aorta, hind limbs, and pancreas. In addition, vascular decellularization of selected organs was performed in situ, within the donor body, achieving better control over the perfusion process. Human placenta-derived endothelial progenitor cells (EPCs) were used as immunologically-acceptable human cells to repopulate the luminal surface of de-endothelialized aorta (in vitro), kidneys, lungs and hind limbs (ex vivo). This study provides evidence that artificially generating vascular chimerism is feasible and could potentially pave the way for crossing the immunological barrier to xenotransplantation, as well as reducing the immunological burden of allogeneic grafts.
Collapse
Affiliation(s)
- Shahar Cohen
- Laboratory for Organ Bioengineering, Rabin Medical Center, Petah Tikva, Israel.
| | - Shirly Partouche
- Laboratory for Organ Bioengineering, Rabin Medical Center, Petah Tikva, Israel.,Felsenstien Medical Research Center, Rabin Medical Center, Petah Tikva, Israel
| | - Michael Gurevich
- Department of Organ Transplantation, Rabin Medical Center, Petah Tikva, Israel
| | - Vladimir Tennak
- Department of Organ Transplantation, Rabin Medical Center, Petah Tikva, Israel
| | - Vadym Mezhybovsky
- Department of Organ Transplantation, Rabin Medical Center, Petah Tikva, Israel
| | - Dmitry Azarov
- Experimental Surgery Unit, Rabin Medical Center, Petah Tikva, Israel
| | | | - Benny Hovav
- Department of Radiology, Rabin Medical Center, Petah Tikva, Israel
| | - Hagit Niv-Drori
- Department of Pathology, Rabin Medical Center, Petah Tikva, Israel
| | - Chana Weiss
- Department of Pathology, Rabin Medical Center, Petah Tikva, Israel
| | - Adi Borovich
- Helen Schneider Hospital for Women, Rabin Medical Center, Petah Tikva, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Guy Cohen
- Helen Schneider Hospital for Women, Rabin Medical Center, Petah Tikva, Israel
| | - Avital Wertheimer
- Helen Schneider Hospital for Women, Rabin Medical Center, Petah Tikva, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Golan Shukrun
- Division of Pediatric Cardiothoracic Surgery, Schneider Children's Medical Center, Petah Tikva, Israel.,Department of Cardiothoracic Surgery, Rabin Medical Center, Petah Tikva, Israel
| | - Moshe Israeli
- Tissue Typing Laboratory, Rabin Medical Center, Petah Tikva, Israel.,Zefat Academic College, Zefat, Israel
| | - Vered Yahalom
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Blood Services and Apheresis Institute, Rabin Medical Center, Petah Tikva, Israel
| | - Dorit Leshem-Lev
- Felsenstien Medical Research Center, Rabin Medical Center, Petah Tikva, Israel.,Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel
| | - Leor Perl
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel
| | - Ran Kornowski
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel
| | - Arnon Wiznitzer
- Helen Schneider Hospital for Women, Rabin Medical Center, Petah Tikva, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Ana Tobar
- Department of Pathology, Rabin Medical Center, Petah Tikva, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Meora Feinmesser
- Department of Pathology, Rabin Medical Center, Petah Tikva, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Eytan Mor
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Transplantation Unit, Department of Surgery B, Sheba Medical Center, Ramat Gan, Israel
| | - Eli Atar
- Department of Radiology, Rabin Medical Center, Petah Tikva, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Eviatar Nesher
- Department of Organ Transplantation, Rabin Medical Center, Petah Tikva, Israel
| |
Collapse
|
10
|
Barki-Harrington L, Baron-Epel O, Shaulov A, Akria L, Barshay Y, Dally N, Deshet D, Inbar T, Koren-Michowitz M, Leiba M, Moshe Y, Shvidel L, Tadmor T, Yagenah S, Zektser M, Preis M, Hellman I, Yahalom V, Aviv A. Willingness and concerns of transfusion-dependent hematological patients toward the option of home transfusion therapy. Palliat Med 2021; 35:927-932. [PMID: 33761783 PMCID: PMC8114422 DOI: 10.1177/02692163211000634] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND One of the main obstacles of providing home-based palliative care to transfusion-dependent hematology patients is the lack of home transfusions services. While healthcare professionals are concerned with safety and cost of home transfusions, the attitude of the patients toward home transfusions are mostly unknown. AIM To obtain quantitative data regarding the willingness and concerns of transfusion-dependent patients with hematological diseases toward the option of home transfusions. DESIGN A cross sectional survey including a self-administered questionnaire in one of the three main spoken languages in Israel was administered to patients in 17 hospital hematology outpatient clinics between May 2019 and March 2020. RESULTS About 52% of 385 patients that participated in the survey preferred home transfusions to hospital transfusions. Gender, age, education, or type of disease were not associated with preference for home transfusions, nor were hospital location or its size. The likelihood to prefer home transfusions was significantly higher among the Hebrew-speakers and those who had not experienced adverse effects previously. The most significant factor associated with preference of home transfusions was a perceived negative effect of hospital-based transfusion on quality of life. The main reason to reject home transfusions was fear of possible adverse effects and concerns over losing contact with the medical staff at the treating hospital. CONCLUSION These data suggest that a significant portion of transfusion-dependent patients in Israel view home transfusions as a preferred treatment option and that its successful implementation requires maintaining ongoing contact with the treating hospital.
Collapse
Affiliation(s)
| | | | - Adir Shaulov
- Department of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Luiza Akria
- Blood Bank and Molecular Hematology Laboratory, Galilee Medical Center, Nahariya, Israel.,Faculty of Medicine in the Galilee, Bar Ilan University, Safed, Israel
| | - Yossef Barshay
- Department of Hematology, Barzilai University Medical Center, Ashkelon, Israel.,Faculty of Health Sciences, Ben Gurion University of the Negev, Be'er-Sheva, Israel
| | - Najib Dally
- Faculty of Medicine in the Galilee, Bar Ilan University, Safed, Israel.,Hematology Institute and Blood Bank, Ziv Medical Center, Safed, Israel
| | - Dana Deshet
- Department of Hematology, Edith Wolfson Medical Center, Holon, Israel.,Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Tsofia Inbar
- Department of Hematology, Rambam Health Care Campus, Haifa, Israel
| | - Maya Koren-Michowitz
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.,Department of Hematology, Shamir Medical Center, Zerifin, Israel
| | - Merav Leiba
- Faculty of Health Sciences, Ben Gurion University of the Negev, Be'er-Sheva, Israel.,Department of Hematology and Blood Bank, Assuta Ashdod University Hospital, Ashdod, Israel
| | - Yakir Moshe
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.,Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
| | - Lev Shvidel
- Hematology Institute, Kaplan Medical Center, Rehovoth, Israel
| | - Tamar Tadmor
- Hematology Unit, Bnai Zion Medical Center, Israel.,The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Shai Yagenah
- Faculty of Medicine in the Galilee, Bar Ilan University, Safed, Israel.,Department of Hemato-Oncology, Padeh Poriah Medical Center, Poriah, Israel
| | - Miri Zektser
- Faculty of Health Sciences, Ben Gurion University of the Negev, Be'er-Sheva, Israel.,Hematology Department, Soroka Medical Center, Be'er Sheva, Israel
| | - Meir Preis
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.,Institute of Hematology, Lady Davis Carmel Medical Center, Haifa, Israel
| | - Ilana Hellman
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.,Department of Hematology, Meir Medical Center, Kefar Sava, Israel
| | - Vered Yahalom
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.,Blood Services & Apheresis Institute, Rabin Medical Center, Petah Tiqva, Israel
| | - Ariel Aviv
- Hematology Unit, HaEmek Medical Center, Afula, Israel
| |
Collapse
|
11
|
Kornowski Cohen M, Sheena L, Shafir Y, Yahalom V, Gafter-Gvili A, Spectre G. An Early Unexpected Immune Thrombotic Thrombocytopenic Purpura Relapse Associated with SARS-CoV-2 Infection: A Case Report and Literature Review. Acta Haematol 2021; 144:678-682. [PMID: 33895748 PMCID: PMC8247821 DOI: 10.1159/000514283] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Accepted: 01/08/2021] [Indexed: 11/19/2022]
Abstract
SARS-CoV-2 has been reported as a possible triggering factor for the development of several autoimmune diseases and inflammatory dysregulation. Here, we present a case report of a woman with a history of systemic lupus erythematosus and antiphospholipid syndrome, presenting with concurrent COVID-19 infection and immune thrombotic thrombocytopenic purpura (TTP). The patient was treated with plasma exchange, steroids, and caplacizumab with initial good response to therapy. The course of both TTP and COVID-19 disease was mild. However, after ADAMTS-13 activity was normalized, the patient experienced an early unexpected TTP relapse manifested by intravascular hemolysis with stable platelet counts requiring further treatment. Only 3 cases of COVID-19 associated TTP were reported in the literature thus far. We summarize the literature and suggest that COVID-19 could act as a trigger for TTP, with good outcomes if recognized and treated early.
Collapse
Affiliation(s)
| | - Liron Sheena
- Medicine F − Recanati, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
| | - Yair Shafir
- Medicine F − Recanati, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
| | - Vered Yahalom
- Blood Services and Apheresis Institute, Rabin Medical Center, Petah Tikva, Israel
- Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Anat Gafter-Gvili
- Medicine A, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
- Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
- Institute of Hematology, Davidoff Cancer Center, Beilinson Campus Rabin Medical Center, Petah Tikva, Israel
| | - Galia Spectre
- Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
- Institute of Hematology, Davidoff Cancer Center, Beilinson Campus Rabin Medical Center, Petah Tikva, Israel
- *Galia Spectre,
| |
Collapse
|
12
|
Izak M, Yahalom V, Maor Y, Zimhoni O, Cohen D, Chen J, Shinar E. [COVID-19 - BLOOD GROUPS, ANTIBODIES AND CONVALESCENT PLASMA]. Harefuah 2021; 160:139-143. [PMID: 33749174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Israel is currently struggling with the Coronavirus Disease (COVID-19) caused by SARS CoV-2. Transmission is increasing, with higher morbidity and mortality among populations at risk. Over-representation of blood type A was reported in COVID-19 patients with increased respiratory failure, while blood type O seems to have a protective effect. This may be caused by interference of anti-A antibodies in viral binding to the ACE receptor, different neutralization antibodies potency or variations in the stability of von Willebrand factor (VWF) multimers in different blood types. Since transfusion of convalescent COVID19 Plasma (CCP) is an accepted therapeutic modality, the Ministry of Health initiated a national project whereby CCP is collected by Magen David Adom (MDA) Blood Services using apheresis procedures and transfusions are approved by an experts committee, as part of the clinical trial or as compassionate treatment. Preliminary analysis of 49/170 patients treated so far shows improvement in 49%, with important relations with the anti-SARS-CoV-2 IgG antibodies level in the transfused plasma. Anti-SARS-CoV-2 antibodies were found in 83% of 1100 CCP donors, but a 13% decrease in antibodies level was detected in repeat donations. Blood type A was more predominant among CCP donors, when compared to MDA blood donors' data. A transfusion of CCP is a feasible and relatively safe therapeutic modality, mainly for patients with moderate COVID 19. CCP also serves as a source for the production of hyperimmune globulin for the treatment of COVID 19 and for passive immunization for populations at risk.
Collapse
Affiliation(s)
| | - Vered Yahalom
- Blood Bank and Apheresis Services, Rabin Medical Center
| | - Yasmin Maor
- Infectious Disease Unit, Wolfson Medical Center, Sackler Faculty of Medicine, Tel Aviv University
| | - Oren Zimhoni
- Infectious Diseases Unit, Kaplan Medical Center, Faculty of Medicine, Hebrew University
| | | | - Jacob Chen
- Medical Directorate, Israel Ministry of Health, Israel Defense Forces, Medical Corps
| | - Eilat Shinar
- Magen David Adom National Blood Services
- Faculty of Health Sciences, Ben Gurion University, Israel
| |
Collapse
|
13
|
Rahimi-Levene N, Chezar J, Yahalom V. Red blood cell alloimmunization prevalence and hemolytic disease of the fetus and newborn in Israel: A retrospective study. Transfusion 2020; 60:2684-2690. [PMID: 32770778 DOI: 10.1111/trf.15987] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2020] [Revised: 06/16/2020] [Accepted: 06/20/2020] [Indexed: 11/28/2022]
Abstract
Hemolytic disease of the fetus and newborn (HDFN) is a severe form of anemia caused by maternal antibodies against fetal red blood cells (RBC) that can cause intrauterine and perinatal morbidity and mortality. The prevalence and specificities of alloantibodies among Israeli pregnant women and clinical outcomes for their fetuses and newborns are unknown. STUDY DESIGN AND METHODS A retrospective study of women who gave birth between January 1, 2011, and December 31, 2011, was performed. Data were obtained for obstetric admissions from 16 of 27 hospitals, which included results of maternal ABO, D, antibody screens, antibody identification, and requirements for intrauterine or newborn exchange transfusions. RESULTS Data on 90 948 women representing 70% of all births during 2011 were analyzed. Antibody screen was positive in 5245 (5.8%) women. Alloantibodies, excluding anti-D titer (<16) were identified in 900 (1.0%) women. Of 191 D- women, 75 (39.3%) had anti-D titer of 16 or greater. Other common clinically significant antibodies were anti-E (204, 23%), anti-K (145, 16%), and anti-c (97, 10.8%) alone or in antibody combinations. Multiple alloantibodies were observed in 132 of 900 (15%) of women. Severe HDFN developed in 6.8% (9/132) of these pregnancies. Seventeen fetuses and newborns (0.02% of births) including one set of twins required RBC transfusions. Two fetuses whose mothers had multiple alloantibodies received intrauterine transfusions; one of them was hydropic and died. CONCLUSION The prevalence of RBC alloantibodies was 1.0% among Israeli pregnant women. Transfusion was required in 0.02% of the fetuses and newborns. Severe HDFN developed in 6.8% of pregnancies with multiple maternal alloantibodies.
Collapse
Affiliation(s)
- Naomi Rahimi-Levene
- Blood Bank, Shamir Medical Center, Zerifin, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Judith Chezar
- Blood Bank, Galilee Medical Center, Nahariya, Israel
| | - Vered Yahalom
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Blood Services and Apheresis Institute, Rabin Medical Center, Petach Tikva, Israel.,National Blood Group Reference Laboratory, Magen David Adom, National Blood Services, Ramat Gan, Israel
| | | |
Collapse
|
14
|
Thornton N, Karamatic Crew V, Tilley L, Green CA, Tay CL, Griffiths RE, Singleton BK, Spring F, Walser P, Alattar AG, Jones B, Laundy R, Storry JR, Möller M, Wall L, Charlewood R, Westhoff CM, Lomas-Francis C, Yahalom V, Feick U, Seltsam A, Mayer B, Olsson ML, Anstee DJ. Disruption of the tumour-associated EMP3 enhances erythroid proliferation and causes the MAM-negative phenotype. Nat Commun 2020; 11:3569. [PMID: 32678083 PMCID: PMC7366909 DOI: 10.1038/s41467-020-17060-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2018] [Accepted: 05/29/2020] [Indexed: 12/14/2022] Open
Abstract
The clinically important MAM blood group antigen is present on haematopoietic cells of all humans except rare MAM-negative individuals. Its molecular basis is unknown. By whole-exome sequencing we identify EMP3, encoding epithelial membrane protein 3 (EMP3), as a candidate gene, then demonstrate inactivating mutations in ten known MAM-negative individuals. We show that EMP3, a purported tumour suppressor in various solid tumours, is expressed in erythroid cells. Disruption of EMP3 by CRISPR/Cas9 gene editing in an immortalised human erythroid cell line (BEL-A2) abolishes MAM expression. We find EMP3 to associate with, and stabilise, CD44 in the plasma membrane. Furthermore, cultured erythroid progenitor cells from MAM-negative individuals show markedly increased proliferation and higher reticulocyte yields, suggesting an important regulatory role for EMP3 in erythropoiesis and control of cell production. Our data establish MAM as a new blood group system and demonstrate an interaction of EMP3 with the cell surface signalling molecule CD44.
Collapse
Affiliation(s)
- Nicole Thornton
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK.
| | - Vanja Karamatic Crew
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK
| | - Louise Tilley
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK
| | - Carole A Green
- Bristol Institute for Transfusion Sciences, NHS Blood and Transplant and NIHR Blood and Transplant Unit in Red Cell Products, University of Bristol, Bristol, UK
| | - Chwen Ling Tay
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK
| | - Rebecca E Griffiths
- Bristol Institute for Transfusion Sciences, NHS Blood and Transplant and NIHR Blood and Transplant Unit in Red Cell Products, University of Bristol, Bristol, UK
| | - Belinda K Singleton
- Bristol Institute for Transfusion Sciences, NHS Blood and Transplant and NIHR Blood and Transplant Unit in Red Cell Products, University of Bristol, Bristol, UK
| | - Frances Spring
- Bristol Institute for Transfusion Sciences, NHS Blood and Transplant and NIHR Blood and Transplant Unit in Red Cell Products, University of Bristol, Bristol, UK
| | - Piers Walser
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK
| | - Abdul Ghani Alattar
- Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden
| | - Benjamin Jones
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK
| | - Rosalind Laundy
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK
| | - Jill R Storry
- Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden
- Department of Clinical Immunology and Transfusion Medicine, Office of Medical Services, Lund, Sweden
| | - Mattias Möller
- Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden
| | - Lorna Wall
- Reference Laboratory, New Zealand Blood Service, Auckland, New Zealand
| | | | | | | | - Vered Yahalom
- Magen David Adom, National Blood Services, Ramat Gan, Israel
| | - Ute Feick
- Deutsches Rotes Kreuz, Blood Donor Service, Institute Bad Kreuznach, Bad Kreuznach, Germany
| | - Axel Seltsam
- German Red Cross Blood Service NSTOB, Institute Springe, Springe, Germany
| | - Beate Mayer
- Institute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Martin L Olsson
- Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden
- Department of Clinical Immunology and Transfusion Medicine, Office of Medical Services, Lund, Sweden
| | - David J Anstee
- Bristol Institute for Transfusion Sciences, NHS Blood and Transplant and NIHR Blood and Transplant Unit in Red Cell Products, University of Bristol, Bristol, UK
| |
Collapse
|
15
|
Pazgal I, Yahalom V, Shalev B, Raanani P, Stark P. Alloimmunization and autoimmunization in adult transfusion-dependent thalassemia patients: a report from a comprehensive center in Israel. Ann Hematol 2020; 99:2731-2736. [PMID: 32488601 DOI: 10.1007/s00277-020-04104-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Accepted: 05/27/2020] [Indexed: 01/24/2023]
Abstract
Patients with beta thalassemia major (TM) are transfusion-dependent (TD) since early childhood and for life. Development of alloantibodies and autoantibodies against red blood cell (RBC) antigens is increasingly recognized as a significant transfusion hazard, especially among heavily transfused patients. The aim of this study is to assess RBC alloimmunization and autoimmunization rates in TD TM patients treated in our Comprehensive Center of Adult Thalassemia, Hemoglobinopathies and Rare Anemias. TD TM patients, regularly transfused every 2-3 weeks, were included in the study. Clinical and RBC transfusion records, including RBC antibodies, since diagnosis in early childhood, were retrieved from patients' files and from the blood bank database. Forty TD TM patients, > 18 years of age, were included in the study. Alloimmunization was demonstrated in 17 (42.5%) patients. Thirty-four alloantibodies were detected, with the most frequent being RH related (12 of 34, 35.3%) followed by those of the Kell system (8 of 34, 23.5%). Age at first transfusion was positively related to the probability of developing alloantibodies (p = 0.02). Splenectomy was found to be correlated with developing alloantibodies (p = 0.016). Logistic regression analysis of the lifelong probability of developing alloantibodies on the age at first transfusion and splenectomy demonstrates a strong positive relationship (p = 0.002). A substantially high rate of alloimmunization was found among adult TD TM patients. Early initiation of RBC transfusions, avoidance of splenectomy and extended Rh and K antigen matching, can reduce the incidence of alloimmunization in TD TM patients.
Collapse
Affiliation(s)
- Idit Pazgal
- Comprehensive Center of Thalassemia, Hemoglobinopathies & Rare Anemias, Institute of Hematology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.,Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Vered Yahalom
- Blood Services and Apheresis Institute, Rabin Medical Center, Petah Tikva, Israel
| | - Bruria Shalev
- Blood Services and Apheresis Institute, Rabin Medical Center, Petah Tikva, Israel
| | - Pia Raanani
- Comprehensive Center of Thalassemia, Hemoglobinopathies & Rare Anemias, Institute of Hematology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.,Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Pinhas Stark
- Comprehensive Center of Thalassemia, Hemoglobinopathies & Rare Anemias, Institute of Hematology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel. .,Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
| |
Collapse
|
16
|
Pasvolsky O, Shepshelovich D, Berger T, Tadmor B, Shochat T, Raanani P, Yahalom V, Gafter-Gvili A. Extended Follow-up of an Educational Intervention Encouraging Appropriate Use of Blood Transfusions. Acta Haematol 2019; 143:446-451. [PMID: 31752009 DOI: 10.1159/000503988] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2019] [Accepted: 10/09/2019] [Indexed: 01/28/2023]
Abstract
INTRODUCTION A restrictive transfusion strategy of packed red blood cells (PRBCs) has been associated with at least non-inferior patient outcomes in a variety of clinical settings. In December 2014, we conducted an educational intervention which consisted of an oral presentation and computerized notifications at a single tertiary medical center. OBJECTIVE The aim of this study was to examine the long-term effects of a simple and low-cost educational intervention aimed to promote awareness to transfusion guidelines. METHODS We retrospectively analyzed all PRBC transfusions ordered between 2014 and 2017. The primary end point was defined as the percentage of PRBC transfused to patients with hemoglobin (Hb) ≥8 g/dL. RESULTS Between 2014 and 2017, a total of 27,475 PRBCs were transfused in our medical center. There was a continuous reduction in the percentage of PRBCs transfused at a Hb level ≥8 g/dL between 2014 and 2017, with a matching increase in the PRBC percentage trans-fused at Hb <7 g/dL (OR reduction of 42%, 95% CI 0.54-0.62 and OR increase of 68% [95% CI 1.56-1.81], respec-tively). CONCLUSION A simple educational intervention likely contributed to sustained improvement in the appropriateness of PRBC transfusions.
Collapse
Affiliation(s)
- Oren Pasvolsky
- Institute of Hematology, Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel,
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel,
| | - Daniel Shepshelovich
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
- Medicine A, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel
| | - Tamar Berger
- Institute of Hematology, Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Boaz Tadmor
- Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel
| | - Tzippy Shochat
- Biostatistical Unit, Rabin Medical Center, Petach Tikva, Israel
| | - Pia Raanani
- Institute of Hematology, Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Vered Yahalom
- Blood Services and Apheresis Institute, Rabin Medical Center, Petach Tikva, Israel
| | - Anat Gafter-Gvili
- Institute of Hematology, Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
- Medicine A, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel
| |
Collapse
|
17
|
Yazer MH, Delaney M, Doughty H, Dunbar NM, Al‐Riyami AZ, Triulzi DJ, Watchko JF, Wood EM, Yahalom V, Emery SP. It is time to reconsider the risks of transfusing RhD negative females of childbearing potential with RhD positive red blood cells in bleeding emergencies. Transfusion 2019; 59:3794-3799. [DOI: 10.1111/trf.15569] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2019] [Revised: 09/21/2019] [Accepted: 09/26/2019] [Indexed: 12/17/2022]
Affiliation(s)
- Mark H. Yazer
- Department of PathologyUniversity of Pittsburgh Pittsburgh Pennsylvania
- Vitalant Pittsburgh Pennsylvania
| | - Meghan Delaney
- Division of Pathology and Laboratory MedicineChildren's National Medical Center Washington District of Columbia
- Department of Pathology and PediatricsGeorge Washington University Medical School Washington District of Columbia
| | | | - Nancy M. Dunbar
- Department of Pathology and Laboratory MedicineDartmouth‐Hitchcock Medical Center Lebanon New Hampshire
| | - Arwa Z. Al‐Riyami
- Department of HematologySultan Qaboos University Hospital Muscat Oman
| | - Darrell J. Triulzi
- Department of PathologyUniversity of Pittsburgh Pittsburgh Pennsylvania
- Vitalant Pittsburgh Pennsylvania
| | - Jon F. Watchko
- Department of PediatricsUniversity of Pittsburgh School of Medicine Pittsburgh Pennsylvania
| | - Erica M. Wood
- Transfusion Research UnitSchool of Public Health and Preventive Medicine, Monash University Melbourne Australia
- Department of Clinical HaematologyMonash Health Melbourne Australia
| | - Vered Yahalom
- Rabin Medical CenterBlood Services and Apheresis Institute Petah Tiqva Israel
| | - Stephen P. Emery
- Department of Obstetrics, Gynecology and Reproductive SciencesUniversity of Pittsburgh School of Medicine Pittsburgh Pennsylvania
| |
Collapse
|
18
|
Barzilai M, Kirgner I, Steimatzky A, Salzer Gotler D, Belnick Y, Shacham-Abulafia A, Avivi I, Raanani P, Yahalom V, Nakav S, Varon D, Yussim E, Bachar GN, Spectre G. Prothrombin Complex Concentrate before Urgent Surgery in Patients Treated with Rivaroxaban and Apixaban. Acta Haematol 2019; 143:266-271. [PMID: 31610537 DOI: 10.1159/000502173] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2019] [Accepted: 07/06/2019] [Indexed: 02/06/2023]
Abstract
INTRODUCTION Patients treated with direct Xa inhibitors may require urgent surgery. Administration of prothrombin complex concentrate (PCC) in this setting is common; however, it is based on limited experience in healthy volunteers. OBJECTIVE To characterize the population receiving PCC for apixaban/rivaroxaban reversal prior to an urgent surgery and evaluate its efficacy and safety. METHODS This was a retrospective study in 2 tertiary hospitals. Bleeding was evaluated based on surgical reports, hemoglobin drop, and the use of blood products or additional PCC during 48 h. Safety measures were thrombotic complications and 30-day mortality. RESULTS Sixty-two patients aged 80.7 ± 9 years, treated with apixaban (39.63%) or rivaroxaban (23.37%), received PCC before an urgent surgery/procedure. Most underwent abdominal operation (61%), orthopedic surgery (13%), or transhepatic cholecystostomy insertion (10%). Bleeding during surgery was reported in 3 patients (5%), no patient required additional PCC, and 16 patients (26%) received packed cells (median: 1 unit, range: 1-5). The 30-day mortality and thrombosis rates were 21% (n = 13) and 3% (n = 2), respectively. The cause of death was related to the primary disease, most commonly sepsis. No patient died due to bleeding/thrombosis. CONCLUSIONS Our results support the use of PCC to achieve hemostasis in patients treated with Xa inhibitors prior to an urgent surgery.
Collapse
Affiliation(s)
- Merav Barzilai
- Institute of Hematology, Sourasky Medical Center, Tel Aviv, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Ilya Kirgner
- Institute of Hematology, Sourasky Medical Center, Tel Aviv, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Arza Steimatzky
- Institute of Hematology, Rabin Medical Center, Petah Tikva, Israel
| | | | - Yulia Belnick
- Internal Medicine D, Rabin Medical Center, Hasharon Hospital, Petah Tikva, Israel
| | - Adi Shacham-Abulafia
- Institute of Hematology, Rabin Medical Center, Petah Tikva, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Irit Avivi
- Institute of Hematology, Sourasky Medical Center, Tel Aviv, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Pia Raanani
- Institute of Hematology, Rabin Medical Center, Petah Tikva, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Vered Yahalom
- Transfusion and Apheresis Service, Rabin Medical Center, Petah Tikva, Israel
| | - Sigal Nakav
- Hemostasis Laboratory, Rabin Medical Center, Petah Tikva, Israel
| | - David Varon
- Institute of Hematology, Sourasky Medical Center, Tel Aviv, Israel
| | - Ethan Yussim
- Department of Radiology, Sourasky Medical Center, Tel Aviv, Israel
| | - Gil N Bachar
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- Department of Radiology, Rabin Medical Center, Petah Tikva, Israel
| | - Galia Spectre
- Institute of Hematology, Rabin Medical Center, Petah Tikva, Israel,
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel,
| |
Collapse
|
19
|
Bruun MT, Yazer MH, Spinella PC, Titlestad K, Lozano M, Delaney M, Lejdarová H, Pavlova D, Trakhtman P, Starostin N, Zhiburt E, van Kraaij MGJ, Huisman E, Kutner JM, Sakashita AM, Yokoyama APH, Zubicaray J, Sevilla J, Okazaki H, Hiwatari M, Nagura Y, Manzini PM, Facco G, Pecoraro C, Singh L, Hans R, Sharma RR, Kumar P, Wikman A, Deschmann E, Kaur H, Mei Lam JC, Ying Ho SK, Koh PL, Moss R, New HV, Kinmonth A, Comande M, Savoia H, Crighton G, Yacobovich J, Yahalom V, Lau W. Vox Sanguinis International Forum on paediatric indications for blood component transfusion. Vox Sang 2019; 114:e36-e90. [PMID: 31087343 DOI: 10.1111/vox.12762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
| | | | | | | | | | - Meghan Delaney
- Pathology & Laboratory Medicine Division, Children's National Health System, Washington, DC, USA.,Transfusion Medicine, Children's National Health System, Washington, DC, USA.,Pathology & Pediatrics, The George Washington University, Washington, DC, USA
| | - Hana Lejdarová
- Transfusion and Tissue Department, University Hospital Brno, Jihlavská 20, Brno, 625 00, Czech Republic
| | - Dana Pavlova
- Blood Transfusion Unit, Department of Health of Moscow, Children's City Clinical Hospital of St. Vladimir, Stroiteley Str/17-1-80, Moscow, 119311, Russia
| | - Pavel Trakhtman
- Russian National Centre for Pediatric Hematology, Oncology and Immunology, 1, Samori Mashela str., Moscow, 117997, Russia
| | - Nikolay Starostin
- Russian National Centre for Pediatric Hematology, Oncology and Immunology, 1, Samori Mashela str., Moscow, 117997, Russia
| | - Eugene Zhiburt
- Pirogov National Medical Surgical Center, 70, Nizhnyaya Pervomayskaya Street, Moscow, Russia
| | - Marian G J van Kraaij
- Donor and Medical Affairs, Sanquin Blood Bank, P.O. Box 9137, Amsterdam, 1006 AC, The Netherlands
| | - Elise Huisman
- Erasmus Medical Centre Rotterdam, Doctor Molewaterplein 40, Rotterdam, 3015 GD, The Netherlands
| | - Jose M Kutner
- Departamento de Hemoterapia, Hospital Israelita Albert Einstein, Av. Albert Einstein, 627 - Banco de Sangue, São Paulo, 05651-091, Brazil
| | - Araci M Sakashita
- Departamento de Hemoterapia, Hospital Israelita Albert Einstein, Av. Albert Einstein, 627 - Banco de Sangue, São Paulo, 05651-091, Brazil
| | - Ana P H Yokoyama
- Hospital Israelita Albert Einstein, Av. Albert Einstein, 627 - Banco de Sangue, São Paulo, 05651-091, Brazil
| | - Josune Zubicaray
- Hematología y Hemoterapia, Hospital Infantil Universitario Niño Jesús, Avenida Menéndez Pelayo 65, Madrid, 28009, Spain
| | - Julián Sevilla
- Hematología y Hemoterapia, Hospital Infantil Universitario Niño Jesús, Avenida Menéndez Pelayo 65, Madrid, 28009, Spain
| | - Hitoshi Okazaki
- Department of Blood Transfusion, The University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Mitsuteru Hiwatari
- Department of Pediatrics, The University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Yutaka Nagura
- Department of Blood Transfusion, The University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Paola Maria Manzini
- SC Banca del Sangue Servizio di Immunoematologia, University Hospital, Città della Salute e della Scienza di Torino, Corso Bramante 88, Torino, 10126, Italy
| | - Giuseppina Facco
- S.S.D. Medicina Trasfusionale Materno Infantile Traumatologica, University Hospital, Città della Salute e della Scienza di Torino, Piazza Polonia 94, Torino, 10126, Italy
| | - Clara Pecoraro
- SC Banca del Sangue Servizio di Immunoematologia, University Hospital, Città della Salute e della Scienza di Torino, Corso Bramante 88, Torino, 10126, Italy
| | - Lakhvinder Singh
- Department of Transfusion Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India
| | - Rekha Hans
- Department of Transfusion Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India
| | - Ratti Ram Sharma
- Department of Transfusion Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India
| | - Praveen Kumar
- Division of Neonatology, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India
| | - Agneta Wikman
- Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.,Division of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Emöke Deschmann
- Division of Paediatric Haematology-Oncology National University Hospital, Paediatric Transfusion Medicine Consultant in NHS Blood and Transplant/Imperial College, Charcot Road, London, NW9 5BG, UK
| | - Hartirathpal Kaur
- Blood Services Group, Health Sciences Authority, 11 Outram Road, Singapore City, 169078, Singapore
| | - Joyce Ching Mei Lam
- Haematology Laboratory and Blood Bank, KK Women's and Children Hospital, 100 Bukit Timah Road, Singapore City, 229899, Singapore.,Paediatric Haematology/Oncology Service, KK Women's and Children Hospital, 100 Bukit Timah Road, Singapore City, 229899, Singapore
| | - Selina Kah Ying Ho
- Department of Neonatology, Singapore General Hospital, Outram Road, Singapore City, 169608, Singapore
| | - Pei Lin Koh
- Division of Paediatric Haematology-Oncology, Department of Paediatrics, National University Hospital, 5 Lower Kent Ridge Road, Singapore City, 119 074, Singapore
| | - Rachel Moss
- Great Ormond Street Hospital for Children NHS Foundation Trust, Camelia Botnar Laboratories, Great Ormond Street, London, WC1N 3JH, UK
| | - Helen V New
- Paediatric Transfusion Medicine, Consultant in NHS Blood and Transplant/Imperial College, Charcot Road, London, NW9 5BG, UK
| | - Anne Kinmonth
- Department of Haematology, Royal Children's Hospital, 50 Flemington Road, Parkville, Vic., 3052, Australia
| | - Mary Comande
- Department of Haematology, Royal Children's Hospital, 50 Flemington Road, Parkville, Vic., 3052, Australia
| | - Helen Savoia
- Department of Haematology, Royal Children's Hospital, 50 Flemington Road, Parkville, Vic., 3052, Australia
| | - Gemma Crighton
- Department of Haematology, Royal Children's Hospital, 50 Flemington Road, Parkville, Vic., 3052, Australia
| | - Joanne Yacobovich
- Department of Pediatric Hematology Oncology, Schneider Children's Medical Center, Petah Tikva, Israel.,Transfusion Committee, Schneider Children's Medical Center, Petah Tikva, Israel.,Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | | | - Wendy Lau
- The Hospital for Sick Children, 555 University Ave, Toronto, ON, M5G 1X8, Canada
| |
Collapse
|
20
|
Bruun MT, Yazer MH, Spinella PC, Titlestad K, Lozano M, Delaney M, Lejdarová H, Pavlova DE, Trakhtman P, Starostin N, Zhiburt E, van Kraaij MGJ, Huisman E, Kutner JM, Sakashita AM, Yokoyama APH, Zubicaray J, Sevilla J, Okazaki H, Hiwatari M, Nagura Y, Manzini PM, Facco G, Avdis C, Singh L, Hans R, Sharma RR, Kumar P, Wikman A, Deschmann E, Kaur H, Mei JLC, Ying SHK, Pei Lin K, New HV, Moss R, Kinmonth A, Comande M, Savoia H, Crighton G, Yacobovich J, Yahalom V, Lau W. Vox Sanguinis International Forum on paediatric indications for blood component transfusion: Summary. Vox Sang 2019; 114:523-530. [PMID: 31087379 DOI: 10.1111/vox.12763] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Mie Topholm Bruun
- Department of Clinical Immunology, Odense University Hospital, Odense, Denmark
| | - Mark H Yazer
- The Institute for Transfusion Medicine, Pittsburgh, PA, USA
| | - Philip C Spinella
- Department of Pediatrics, Division of Critical Care Medicine, Washington University in St Louis, St Louis, MO, USA
| | - Kjell Titlestad
- Department of Clinical Immunology, Odense University Hospital, Odense, Denmark
| | - Miquel Lozano
- Department of Hemotherapy and Hemostasis, Hospital Clinic, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Storry JR, Clausen FB, Castilho L, Chen Q, Daniels G, Denomme G, Flegel WA, Gassner C, de Haas M, Hyland C, Yanli J, Keller M, Lomas-Francis C, Nogues N, Olsson ML, Peyrard T, van der Schoot E, Tani Y, Thornton N, Wagner F, Weinstock C, Wendel S, Westhoff C, Yahalom V. International Society of Blood Transfusion Working Party on Red Cell Immunogenetics and Blood Group Terminology: Report of the Dubai, Copenhagen and Toronto meetings. Vox Sang 2018; 114:95-102. [PMID: 30421425 DOI: 10.1111/vox.12717] [Citation(s) in RCA: 56] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2018] [Accepted: 09/17/2018] [Indexed: 11/29/2022]
Abstract
BACKGROUND AND OBJECTIVES The International Society of Blood Transfusion (ISBT) Working Party for Red Cell Immunogenetics and Blood Group Terminology meets in association with the ISBT congress and has met three times since the last report: at the international meetings held in Dubai, United Arab Emirates, September 2016 and Toronto, Canada, June 2018; and at a regional congress in Copenhagen, Denmark, June 2017 for an interim session. METHODS As in previous meetings, matters pertaining to blood group antigen nomenclature and classification were discussed. New blood group antigens were approved and named according to the serologic and molecular evidence presented. RESULTS AND CONCLUSIONS Fifteen new blood group antigens were added to eight blood group systems. One antigen was made obsolete based on additional data. Consequently, the current total of blood group antigens recognized by the ISBT is 360, of which 322 are clustered within 36 blood groups systems. The remaining 38 antigens are currently unassigned to a known system. Clinically significant blood group antigens continue to be discovered, through serology/sequencing and/or recombinant or genomic technologies.
Collapse
Affiliation(s)
- Jill R Storry
- Department of Clinical Immunology and Transfusion Medicine, Office for Medical Services, Lund, Sweden
| | - Frederik Banch Clausen
- Department of Clinical Immunology, Laboratory of Blood Genetics, Copenhagen University Hospital, Copenhagen, Denmark
| | | | - Qing Chen
- Jiangsu Province Blood Center, Nanjing, Jiangsu, China
| | - Geoff Daniels
- Bristol Institute for Transfusion Sciences, NHS Blood and Transplant, Bristol, UK
| | | | - Willy A Flegel
- Department of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, MD, USA
| | | | - Masja de Haas
- Sanquin Blood Supply Foundation, Amsterdam, The Netherlands
| | | | - Ji Yanli
- Institute of Clinical Blood Transfusion Guangzhou Blood Center, Guangzhou, China
| | | | | | | | - Martin L Olsson
- Department of Clinical Immunology and Transfusion Medicine, Office for Medical Services, Lund, Sweden.,Department of Laboratory Medicine, Division of Hematology and Transfusion Medicine, Lund University, Lund, Sweden
| | - Thierry Peyrard
- Laboratoire d'Excellence GR-Ex, Institut National de la Transfusion Sanguine, Département Centre National de Référence pour les Groupes Sanguin, UMR_S1134 Inserm, Université Paris Diderot, Paris, France
| | | | | | - Nicole Thornton
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK
| | | | | | | | | | | |
Collapse
|
22
|
Yahalom V, Pillar N, Zhao Y, Modan S, Fang M, Yosephi L, Asher O, Shinar E, Celniker G, Resnik-Wolf H, Brantz Y, Hauschner H, Rosenberg N, Cheng L, Shomron N, Pras E. SMYD1 is the underlying gene for the AnWj-negative blood group phenotype. Eur J Haematol 2018; 101:496-501. [PMID: 29956848 DOI: 10.1111/ejh.13133] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2018] [Revised: 06/22/2018] [Accepted: 06/24/2018] [Indexed: 11/30/2022]
Abstract
BACKGROUND AnWj is a high-incidence blood group antigen associated with three clinical disorders: lymphoid malignancies, immunologic disorders, and autoimmune hemolytic anemia. The aim of this study was to determine the genetic basis of an inherited AnWj-negative phenotype. METHODS We identified a consanguineous family with two AnWj-negative siblings and 4 additional AnWj-negative individuals without known familial relationship to the index family. We performed exome sequencing in search for rare homozygous variants shared by the two AnWj-negative siblings of the index family and searched for these variants in the four non-related AnWj-negative individuals. RESULTS Exome sequencing revealed seven candidate genes that showed complete segregation in the index family and for which the two AnWj-negative siblings were homozygous. However, the four additional non-related AnWj-negative subjects were homozygous for only one of these variants, rs114851602 (R320Q) in the SMYD1 gene. Considering the frequency of the minor allele, the chance of randomly finding 4 consecutive such individuals is 2.56 × 10-18 . CONCLUSION We present genetic and statistical evidence that the R320Q substitution in SMYD1 underlies an inherited form of the AnWj-negative blood group phenotype. The mechanism by which the mutation leads to this phenotype remains to be determined.
Collapse
Affiliation(s)
- Vered Yahalom
- Magen David Adom (MDA) National Blood Services, Tel Hashomer, Ramat Gan, Israel
| | - Nir Pillar
- Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Yingying Zhao
- School of Medicine, Health Science Centre, Shenzhen University, Shenzhen, China
| | - Shirley Modan
- Magen David Adom (MDA) National Blood Services, Tel Hashomer, Ramat Gan, Israel
| | - Mingyan Fang
- BGI-Shenzhen, Shenzhen, China.,The Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
| | - Lydia Yosephi
- Magen David Adom (MDA) National Blood Services, Tel Hashomer, Ramat Gan, Israel
| | - Orna Asher
- Magen David Adom (MDA) National Blood Services, Tel Hashomer, Ramat Gan, Israel
| | - Eilat Shinar
- Magen David Adom (MDA) National Blood Services, Tel Hashomer, Ramat Gan, Israel
| | - Gershon Celniker
- Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Haike Resnik-Wolf
- The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
| | - Yael Brantz
- Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.,The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
| | - Hagit Hauschner
- Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.,The Amalia Biron Research Institute of Thrombosis and Hemostasis, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
| | - Nurit Rosenberg
- Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.,The Amalia Biron Research Institute of Thrombosis and Hemostasis, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
| | - Le Cheng
- BGI-Shenzhen, Shenzhen, China.,The Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
| | - Noam Shomron
- Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Elon Pras
- Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.,The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
| |
Collapse
|
23
|
Kurolap A, Eshach-Adiv O, Hershkovitz T, Paperna T, Mory A, Oz-Levi D, Zohar Y, Mandel H, Chezar J, Azoulay D, Peleg S, Half EE, Yahalom V, Finkel L, Weissbrod O, Geiger D, Tabib A, Shaoul R, Magen D, Bonstein L, Mevorach D, Baris HN. Loss of CD55 in Eculizumab-Responsive Protein-Losing Enteropathy. N Engl J Med 2017; 377:87-89. [PMID: 28657861 DOI: 10.1056/nejmc1707173] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- Alina Kurolap
- Technion-Israel Institute of Technology, Haifa, Israel
| | | | | | | | - Adi Mory
- Rambam Health Care Campus, Haifa, Israel
| | | | | | | | | | | | | | | | - Vered Yahalom
- Magen David Adom National Blood Services, Ramat Gan, Israel
| | - Lilach Finkel
- Magen David Adom National Blood Services, Ramat Gan, Israel
| | | | - Dan Geiger
- Technion-Israel Institute of Technology, Haifa, Israel
| | - Adi Tabib
- Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Ron Shaoul
- Rambam Health Care Campus, Haifa, Israel
| | | | | | - Dror Mevorach
- Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | | |
Collapse
|
24
|
Yazer MH, van de Watering L, Lozano M, Sirdesai S, Rushford K, Wood EM, Yokoyama AP, Kutner JM, Lin Y, Callum J, Cserti-Gazdewich C, Lieberman L, Pendergrast J, Pendry K, Murphy MF, Selleng K, Greinacher A, Marwaha N, Sharma R, Jain A, Orlin Y, Yahalom V, Perseghin P, Incontri A, Masera N, Okazaki H, Ikeda T, Nagura Y, Zwaginga JJ, Pogłod R, Rosiek A, Letowska M, Yuen J, Cid J, Harm SK, Adhikari P. Development of RBC transfusion indications and the collection of patient-specific pre-transfusion information. Vox Sang 2017; 112:e22-e47. [PMID: 28524359 DOI: 10.1111/vox.12509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
| | | | | | - S Sirdesai
- Department of Clinical Haematology, Monash Health, Melbourne, Victoria, Australia
| | - K Rushford
- Monash Pathology, Monash Health, Melbourne, Victoria, Australia
| | - E M Wood
- Department of Clinical Haematology Monash Health and Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
| | - A P Yokoyama
- Hemotherapy and Cell Therapy Department, Hospital Israelita Albert Einstein, Av. Albert Einstein, 627 - Bloco E, São Paulo, SP, 05651-901, Brazil
| | - J M Kutner
- Hemotherapy and Cell Therapy Department, Hospital Israelita Albert Einstein, Av. Albert Einstein, 627 - Bloco E, São Paulo, SP, 05651-901, Brazil
| | - Y Lin
- Department of Clinical Pathology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Room B2-04, Toronto, ON, Canada.,Department of Laboratory Medicine and Pathobiology, University of Toronto, 2075 Bayview Avenue, Room B2-04, Toronto, ON, M4N 3M5, Canada
| | - J Callum
- Department of Clinical Pathology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Room B2-04, Toronto, ON, Canada
| | - C Cserti-Gazdewich
- Department of Medicine / Laboratory Medicine & Pathobiology, University of Toronto, Toronto General Hospital 3EC-306, 200 Elizabeth Street, Toronto, ON, Canada, M5G-2C4.,Laboratory Medicine Program, Laboratory Hematology: Blood Transfusion Laboratory, University Health Network, Toronto General Hospital 3EC-306, 200 Elizabeth Street, Toronto, ON, Canada, M5G-2C4
| | - L Lieberman
- Department of Laboratory Hematology (Transfusion Medicine), University Health Network, 200 Elizabeth Street, Suite 306, Toronto, ON, Canada, M5G 2C4
| | - J Pendergrast
- Department of Laboratory Hematology (Transfusion Medicine), University Health Network, 200 Elizabeth Street, Suite 306, Toronto, ON, Canada, M5G 2C4
| | - K Pendry
- Central Manchester University Hospitals, NHS Foundation Trust, Oxford Rd, Manchester, M13 9WL.,NHS Blood and Transplant Manchester Blood Centre, Plymouth Grove, Manchester, M13 9LL, UK
| | - M F Murphy
- Blood Transfusion Medicine, University of Oxford, Headley Way, Headington, Oxford, OX3 9BQ, UK.,NHS Blood andTransplant and Oxford University Hospitals NHS Foundation Trust, Headley Way, Headington, Oxford, OX3 9BQ, UK.,NHS Blood & Transplant, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9BQ, UK
| | - K Selleng
- Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald, Sauerbruchstrasse, 17475, Greifswald, Germany
| | - A Greinacher
- Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald, Sauerbruchstrasse, 17475, Greifswald, Germany
| | - N Marwaha
- Department of Transfusion Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India
| | - R Sharma
- Department of Transfusion Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India
| | - A Jain
- Department of Transfusion Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India
| | - Y Orlin
- Transfusion & Apheresis Services, Rabin Medical Center, Petach Tikva, Israel
| | - V Yahalom
- Transfusion & Apheresis Services, Rabin Medical Center, Petach Tikva, Israel
| | - P Perseghin
- UOS Aferesi e nuove tecnologie trasfusionali-Laboratorio di Criobiologia, ASST-Monza Ospedale San Gerardo, Via Pergolesi 33, Monza (MB), 20900, Italy
| | - A Incontri
- UOS Aferesi e nuove tecnologie trasfusionali, ASST-Monza Ospedale San Gerardo, Via Pergolesi 33, Monza (MB), 20900, Italy
| | - N Masera
- Clinica Pediatrica, Università di Milano Bicocca and A. O. San Gerardo, Via Pergolesi 33, Monza (MB), 20900, Italy
| | - H Okazaki
- Department of Blood Transfusion, The University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - T Ikeda
- Department of Blood Transfusion, The University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Y Nagura
- Department of Blood Transfusion, The University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - J J Zwaginga
- Department of Immunohematology and Bloodtransfusion, Center for Stem Cell Therapies, Leiden University Medical Center, Albinusdreef 2, Building 1, E3-Q P.O. Box 9600, 2300, RC Leiden, The Netherlands
| | - R Pogłod
- Department of Transfusion Medicine, Institute of Hematology and Transfusion Medicine, ul. Indira Gandhi 14, Warsaw, 02-776, Poland
| | - A Rosiek
- Department for Quality Assurance and Organization of Blood Transfusion Service, Institute of Hematology and Transfusion Medicine, ul. Indira Gandhi 14, Warsaw, 02-776, Poland
| | - M Letowska
- Department for Diagnostics for Hematology and Transfusion Service, Institute of Hematology and Transfusion Medicine, ul. Indira Gandhi 14, Warsaw, 02-776, Poland
| | - J Yuen
- Blood Transfusion Services, Department of Laboratory Medicine, Tan Tock Seng Hospital, Level 2 - Podium Block, 11 Jalan Tan Tock Seng, 308433, Singapore
| | - J Cid
- Apheresis Unit, Department of Hemotherapy and Hemostasis, Hospital Clínic, Villarroel 170, 08036 Barcelona, Catalonia, Spain
| | - S K Harm
- University of Vermont Medical Center, 111 Colchester Avenue, Burlington, VT, 05401, USA
| | - P Adhikari
- University of Vermont Medical Center, 111 Colchester Avenue, Burlington, VT, 05401, USA
| |
Collapse
|
25
|
Yazer MH, van de Watering L, Lozano M, Sirdesai S, Rushford K, Wood EM, Yokoyama AP, Kutner JM, Lin Y, Callum J, Cserti-Gazdewich C, Lieberman L, Pendergrast J, Pendry K, Murphy MF, Selleng K, Greinacher A, Marwaha N, Sharma R, Jain A, Orlin Y, Yahalom V, Perseghin P, Incontri A, Masera N, Okazaki H, Ikeda T, Nagura Y, Zwaginga JJ, Pogłod R, Rosiek A, Letowska M, Yuen J, Cid J, Harm SK, Adhikari P. Development of RBC transfusion indications and the collection of patient-specific pre-transfusion information: summary. Vox Sang 2017; 112:487-494. [PMID: 28524235 DOI: 10.1111/vox.12496] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- M H Yazer
- The Institute for Transfusion Medicine, University of Pittsburgh and University of Southern Denmark, 3636 Blvd of the Allies, Pittsburgh, PA, 15213, USA
| | - L van de Watering
- Jon J van Rood Center for Clinical Transfusion Research, Sanquin - LUMC, Plesmaniaan 1a, Leiden, 2333 BZ, the Netherlands
| | - M Lozano
- Department of Hemotherapy and Hemostasis, University Clinic Hospital, Villaroel 170, Barcelona, 08036, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Yazer MH, Lozano M, Fung M, Kutner J, Murphy MF, Oveland Apelseth T, Pogłód R, Selleng K, Tinmouth A, Wendel S, Yahalom V. An international survey on the role of the hospital transfusion committee. Transfusion 2017; 57:1280-1287. [PMID: 28236313 DOI: 10.1111/trf.14033] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2016] [Revised: 12/21/2016] [Accepted: 12/21/2016] [Indexed: 12/01/2022]
Abstract
BACKGROUND Hospital transfusion committees (HTCs) can oversee all aspects of transfusion practice at a hospital. This survey sought to identify which quality variables were being reported at HTCs around the world. STUDY DESIGN AND METHODS A working party composed of members of the Biomedical Excellence for Safer Transfusion (BEST) collaborative developed a survey of quality variables that could be potentially presented at HTC meetings. The survey was electronically sent to all BEST members who were encouraged to complete it if they were active on an HTC and to send it to other colleagues with similar experience. An expert panel was convened to determine which quality variables are the most important for review at HTC meetings. RESULTS There were 121 respondents; the majority were from Europe (52%), Asia (19%), or North America (19%). Most respondents (68%) were at university hospitals. Of the 117 (97%) respondents with an HTC, the committee most often met quarterly (42%) and reviewed transfusion reactions (79%) and risk management-reported events (52%). The HTCs most commonly included transfusion medicine physicians, anesthesiologists, and other physicians who regularly transfuse blood products. Some of the most commonly reported quality variables included number of blood products transfused, wasted, and expired and the number of improperly labeled specimens. The expert panel analysis revealed that some variables that were deemed important were not being frequently reported at HTCs. CONCLUSION There is variability in the variables being reported at HTCs around the world with some important variables not frequently reported.
Collapse
Affiliation(s)
- Mark H Yazer
- Department of Pathology, University of Pittsburgh and the Institute for Transfusion Medicine, Pittsburgh, Pennsylvania
| | - Miguel Lozano
- Department of Hemotherapy and Hemostasis, University Clinic Hospital, IDIBAPS, University of Barcelona, Barcelona, Spain
| | - Mark Fung
- University of Vermont Medical Center, Burlington, Vermont
| | - Jose Kutner
- Department of Hemotherapy and Cell Therapy, Hospital Israelita Albert Einstein, Sao Paulo, Brazil
| | - Michael F Murphy
- NHS Blood & Transplant, Oxford University Hospitals NHS Foundation Trust, and University of Oxford, Oxford, UK
| | - Torunn Oveland Apelseth
- Laboratory of Clinical Biochemistry and Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway
| | - Ryszard Pogłód
- Department of Transfusion Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
| | - Kathleen Selleng
- Department of Transfusion Medicine, Institute of Immunology and Transfusion Medicine, University Medicine Greifswald, Greifswald, Germany
| | - Alan Tinmouth
- Department of Medicine and Department of Laboratory Medicine & Pathology, University of Ottawa, Ottawa, Ontario, Canada
| | | | - Vered Yahalom
- Department of Transfusion Medicine and Apheresis, Rabin Medical Center, Petach Tikva, Israel
| | | |
Collapse
|
27
|
Aviner S, Cohen O, El-Ubra F, Yahalom V, Bibi H, Zangen S. [DIVERSITY IN PRODUCT SELECTION AND THRESHOLDS FOR PLATELETS TRANSFUSION IN NEONATES AND PREMATURE INFANTS]. Harefuah 2016; 155:466-469. [PMID: 28530325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
INTRODUCTION Many premature and full-term newborns receive prophylactic platelet transfusions to prevent bleeding, particularly the most prevalent one, i.e, intracranial hemorrhages. However, the platelet count threshold above which bleeding is prevented and the efficacy of platelet transfusion in thrombocytopenic neonates, have yet to be established. Therefore, inter-Neonatal Intensive Care Units (NICU) variations in treatment indications and practices are expected. Considerable inter-NICU variations will emphasize the need for guidelines on platelet transfusions to neonates and premature infants. AIMS To examine platelet products selection and indications for transfusion among neonatologists in Israel. Research and Methods: Electronic questionnaires addressing the choice of platelet products and the platelet count threshold for transfusion in various clinical settings were sent to 25 neonatal units. RESULTS All 25 neonatal units responded (100% response rate). There was considerable variation in product selection among the different neonatal units. Up to 24% of the participating units reported selecting nontraditional products. Variation was also found in thresholds for platelet transfusion - several units used high thresholds while others used low ones. Traditional guidelines were followed in up to 64% of cases in selected clinical scenarios. CONCLUSIONS There is considerable variation in both platelet product selection and platelet count thresholds for transfusion among the different neonatal units. DISCUSSION A low threshold for platelet transfusion increases the risk for bleeding, whereas a high threshold increases the prevalence of complications from transfusion of blood products. Adherence to guidelines may prevent both such sequelae. Summary: Such variation in platelet transfusion among neonatologists emphasizes the need for an accepted policy. We recommend setting up a committee of neonatologists, pediatric hematologists and blood service experts which aims to establish an appropriate policy regarding the prevention of platelet transfusion sequelae in newborns.
Collapse
Affiliation(s)
- Shraga Aviner
- The Department of Pediatrics, The Barzilai University Medical Center, Ashkelon
- The Faculty of Health Science, Ben Gurion University of the Negev, Beer Sheva
| | - Ornit Cohen
- Research
- Development Authority, the Barzilai University Medical Center, Ashkelon
| | - Faid El-Ubra
- The Department of Pediatrics, The Barzilai University Medical Center, Ashkelon
| | - Vered Yahalom
- Magen David Adom - National Blood Services, Tel Hashomer, Ramat Gan
| | - Haim Bibi
- The Department of Pediatrics, The Barzilai University Medical Center, Ashkelon
- The Faculty of Health Science, Ben Gurion University of the Negev, Beer Sheva
| | - Shmuel Zangen
- The Faculty of Health Science, Ben Gurion University of the Negev, Beer Sheva
- Neonatal Intensive Care Department, The Barzilai University Medical
| |
Collapse
|
28
|
Storry JR, Castilho L, Chen Q, Daniels G, Denomme G, Flegel WA, Gassner C, de Haas M, Hyland C, Keller M, Lomas-Francis C, Moulds JM, Nogues N, Olsson ML, Peyrard T, van der Schoot CE, Tani Y, Thornton N, Wagner F, Wendel S, Westhoff C, Yahalom V. International society of blood transfusion working party on red cell immunogenetics and terminology: report of the Seoul and London meetings. ACTA ACUST UNITED AC 2016; 11:118-122. [PMID: 29093749 DOI: 10.1111/voxs.12280] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The Working Party has met twice since the last report: in Seoul, South Korea 2014, and in London, UK 2015, both in association with the International Society of Blood Transfusion (ISBT) Congress. As in previous meetings, matters pertaining to blood group antigen nomenclature were discussed. Eleven new blood group antigens were added to seven blood group systems. This brings the current total of blood group antigens recognized by the ISBT to 346, of which 308 are clustered within 36 blood groups systems. The remaining 38 antigens are currently unassigned to a known blood group system.
Collapse
Affiliation(s)
- J R Storry
- Department of Clinical Immunology and Transfusion Medicine, Office for Medical Services, Lund, Sweden
| | - L Castilho
- University of Campinas/Hemocentro, Campinas, Brazil
| | - Q Chen
- Jiangsu Province Blood Center, Nanjing, China
| | - G Daniels
- Bristol Institute for Transfusion Sciences, NHS Blood and Transplant, Bristol, UK
| | - G Denomme
- Blood Center of Wisconsin, Milwaukee, WI, USA
| | - W A Flegel
- Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, USA
| | - C Gassner
- Blutspende Zurich, Zurich, Switzerland
| | - M de Haas
- Sanquin Blood Supply Foundation, Amsterdam, The Netherlands
| | - C Hyland
- Australian Red Cross Blood Services, Brisbane, Qld, Australia
| | - M Keller
- American Red Cross Blood Services, Philadelphia, PA, USA
| | | | | | - N Nogues
- Banc de Sang i Teixits, Barcelona, Spain
| | - M L Olsson
- Department of Laboratory Medicine, Division of Hematology and Transfusion Medicine, Lund University, Lund, Sweden
| | - T Peyrard
- Institut National de la Transfusion Sanguine, Département Centre National de Référence pour les Groupes Sanguins, Inserm UMR_S1134, Paris, France
| | | | - Y Tani
- Osaka Red Cross Blood Center, Osaka, Japan
| | - N Thornton
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK
| | - F Wagner
- Red Cross Blood Service NSTOB, Springe, Germany
| | - S Wendel
- Blood Bank, Hospital Sirio-Libanes, São Paulo, Brazil
| | - C Westhoff
- New York Blood Center, New York, NY, USA
| | - V Yahalom
- NBGRL Magen David Adom, Ramat Gan, Israel
| |
Collapse
|
29
|
Yazer MH, Jackson B, Beckman N, Chesneau S, Bowler P, Delaney M, Devine D, Field S, Germain M, Murphy MF, Sayers M, Shaz B, Shinar E, Takanashi M, Vassallo R, Wickenden C, Yahalom V, Land K. Changes in blood center red blood cell distributions in the era of patient blood management: the trends for collection (TFC) study. Transfusion 2016; 56:1965-73. [DOI: 10.1111/trf.13696] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2016] [Revised: 04/14/2016] [Accepted: 04/15/2016] [Indexed: 11/30/2022]
Affiliation(s)
- Mark H. Yazer
- The Institute for Transfusion Medicine; Pittsburgh Pennsylvania
| | - Bryon Jackson
- The Institute for Transfusion Medicine; Pittsburgh Pennsylvania
| | - Neil Beckman
- Australian Red Cross Blood Service; Melbourne Victoria Australia
| | - Stuart Chesneau
- Australian Red Cross Blood Service; Melbourne Victoria Australia
| | | | | | - Dana Devine
- Canadian Blood Services; Vancouver British Columbia Canada
| | | | | | | | - Merlyn Sayers
- Carter BloodCare and the University of Texas Southwestern; Dallas Texas
| | - Beth Shaz
- New York Blood Center; New York New York
| | - Eilat Shinar
- Magen David Adom, National Blood Services; Ramat Gan Israel
| | | | | | | | - Vered Yahalom
- Magen David Adom, National Blood Services; Ramat Gan Israel
| | - Kevin Land
- United Blood Services; Scottsdale Arizona
| | | |
Collapse
|
30
|
Yahalom V, Finkel L, Shinar E, Asher O. The Israeli rare donor blood program. Immunohematology 2016; 32:11-12. [PMID: 27858421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Affiliation(s)
- Vered Yahalom
- Medical Director, National Blood Group Reference Laboratory, Magen David Adom-National Blood Services
| | | | | | - Orna Asher
- Director, National Blood Group Reference Laboratory, Magen David Adom-National Blood Services
| |
Collapse
|
31
|
Nance S, Scharberg EA, Thornton N, Yahalom V, Sareneva I, Lomas-Francis C. International rare donor panels: a review. Vox Sang 2015; 110:209-18. [DOI: 10.1111/vox.12357] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2015] [Revised: 08/11/2015] [Accepted: 09/20/2015] [Indexed: 12/27/2022]
Affiliation(s)
- S. Nance
- IRL; Biomedical Services; American Red Cross; Philadelphia PA USA
| | - E. A. Scharberg
- Institute for Transfusion Medicine and Immunohematology; Red Cross Transfusion Service of Baden-Wuerttemberg-Hessen gGmbH; Baden-Baden Germany
| | - N. Thornton
- The International Blood Group Reference Laboratory; NHS Blood and Transplant; Filton Bristol UK
| | - V. Yahalom
- National Blood Services; Ramat Gan Israel
| | - I. Sareneva
- Blood Group Unit; Finnish Red Cross Blood Service; Helsinki Finland
| | - C. Lomas-Francis
- New York Blood Center; Laboratory of Immunohematology and Genomics; Long Island City NY USA
| |
Collapse
|
32
|
Balicer RD, Grotto I, Huerta M, Leventhal A, Zach R, Yahalom V, Cohen D. Beveled Needle Technique is Not Associated with Low Take Rates in Israeli Smallpox Revaccination Campaign. Human Vaccines 2014; 1:224-7. [PMID: 17012858 DOI: 10.4161/hv.1.6.2279] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND In its first large-scale smallpox vaccination campaign in the 20(th) century, Israel has experienced an exceptionally high rate of failure to achieve clinical take following vaccination. It was hypothesized that this failure rates might be attributed to the unique vaccination technique adopted in Israel, of using beveled needles rather than bifurcated needles. MATERIALS AND METHODS We retrospectively identified two cohorts vaccinated in the defined dates during the Israeli revaccination campaign, in which beveled needles and bifurcated needles were used alternately, and studied the impact of different covariates on clinical vaccination outcome measures. RESULTS Of 116 subjects that were vaccinated within the defined dates, 46 were vaccinated using bifurcated needles, and 70 by beveled needles. 'Take' rates in subjects vaccinated up to 20 years earlier was 77.5%, compared with 97.2% among those vaccinated in the more distant past (p = 0.001). In multivariate analyses, vaccination 'take' was independently associated with a shorter time from previous vaccination (p = 0.013), but not with gender, birth country, vaccinator or the vaccination technique used. CONCLUSIONS The low take rates observed in the Israeli smallpox revaccination campaign could not be attributed to the unique local vaccination technique, and was most likely induced by a higher rate of residual immunity among vaccinees, compared with the US, as well as by the lower vaccine concentrations used in Israel. In countries and circumstances when bifurcated needles are not sufficiently available, the beveled needle technique may be considered an appropriate alternative.
Collapse
Affiliation(s)
- Ran D Balicer
- Army Health Branch, Medical Corps, Israeli Defense Forces, Be'er-Sheva, Israel.
| | | | | | | | | | | | | |
Collapse
|
33
|
Storry JR, Castilho L, Daniels G, Flegel WA, Garratty G, de Haas M, Hyland C, Lomas-Francis C, Moulds JM, Nogues N, Olsson ML, Poole J, Reid ME, Rouger P, van der Schoot E, Scott M, Tani Y, Yu LC, Wendel S, Westhoff C, Yahalom V, Zelinski T. International Society of Blood Transfusion Working Party on red cell immunogenetics and blood group terminology: Cancun report (2012). Vox Sang 2014; 107:90-6. [PMID: 24372289 PMCID: PMC5661873 DOI: 10.1111/vox.12127] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2013] [Accepted: 11/14/2013] [Indexed: 12/22/2022]
Abstract
The International Society of Blood Transfusion Working Party on red cell immunogenetics and blood group terminology convened during the International congress in Cancun, July 2012. This report details the newly identified antigens in existing blood group systems and presents three new blood group systems.
Collapse
Affiliation(s)
- J R Storry
- Clinical Immunology and Transfusion Medicine, University and Regional Laboratories, Lund, Sweden
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Loewenthal R, Rosenberg N, Kalt R, Dardik R, Landau M, Yahalom V, Avishai O, Frenkel O, Gazit E, Steinberg DM, Lipitz S, Salomon O. Compound heterozygosity of HLA-DRB3*01:01 and HLA-DRB4*01:01 as a potential predictor of fetal neonatal alloimmune thrombocytopenia. Transfusion 2012; 53:344-52. [DOI: 10.1111/j.1537-2995.2012.03734.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
35
|
Roth WK, Busch MP, Schuller A, Ismay S, Cheng A, Seed CR, Jungbauer C, Minsk PM, Sondag-Thull D, Wendel S, Levi JE, Fearon M, Delage G, Xie Y, Jukic I, Turek P, Ullum H, Tefanova V, Tilk M, Reimal R, Castren J, Naukkarinen M, Assal A, Jork C, Hourfar MK, Michel P, Offergeld R, Pichl L, Schmidt M, Schottstedt V, Seifried E, Wagner F, Weber-Schehl M, Politis C, Lin CK, Tsoi WC, O'Riordan J, Gottreich A, Shinar E, Yahalom V, Velati C, Satake M, Sanad N, Sisene I, Bon AH, Koppelmann M, Flanagan P, Flesland O, Brojer E, Lętowska M, Nascimento F, Zhiburt E, Chua SS, Teo D, Stezinar SL, Vermeulen M, Reddy R, Park Q, Castro E, Eiras A, Gonzales Fraile I, Torres P, Ekermo B, Niederhauser C, Chen H, Oota S, Brant LJ, Eglin R, Jarvis L, Mohabir L, Brodsky J, Foster G, Jennings C, Notari E, Stramer S, Kessler D, Hillyer C, Kamel H, Katz L, Taylor C, Panzer S, Reesink HW. International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang 2011; 102:82-90. [PMID: 21933190 DOI: 10.1111/j.1423-0410.2011.01506.x] [Citation(s) in RCA: 146] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
36
|
Wussuki-Lior O, Abu-Horowitz A, Netzer I, Almer Z, Morad Y, Goldich Y, Yahalom V, Pras E, Pras E. Hematologic biomarkers in childhood cataracts. Mol Vis 2011; 17:1011-5. [PMID: 21541272 PMCID: PMC3084226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2011] [Accepted: 04/11/2011] [Indexed: 11/29/2022] Open
Abstract
PURPOSE To date, more than thirty nine genetic loci have been associated with congenital cataracts. Despite this progress, current diagnostic techniques are insufficient for unraveling the underlying genetic defect in sporadic patients and small families. In the present manuscript we demonstrate the contribution of routine laboratory tests in the search for genetic defects of childhood cataracts. METHODS Two families with congenital cataracts and hematologic findings that included hyperferritinemia and the "ii" blood type underwent detailed ophthalmologic and clinical examinations. Mutation analysis of the ferritin light chain (FTL) and glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (GCNT2) genes was performed in the two families, respectively. RESULTS In the family with the "ii" blood group we found a novel GCNT2 mutation c.G935A (p.G312D) in the cataract patients, while in the family with hyperferritinemia cataract syndrome we identified a G→C heterozygous mutation at position +32 of FTL. CONCLUSIONS Hematologic biomarkers may simplify the search for the underlying molecular defect in families with congenital cataract.
Collapse
Affiliation(s)
- O. Wussuki-Lior
- Department of Ophthalmology, Assaf Harofeh Medical Center, Zerifin, Israel
| | - A. Abu-Horowitz
- Sheba Medical Center, Danek Gartener Institute of Human Genetics, Tel Hashomer, Israel
| | - I. Netzer
- Sheba Medical Center, Danek Gartener Institute of Human Genetics, Tel Hashomer, Israel
| | - Z. Almer
- Department of Ophthalmology, Assaf Harofeh Medical Center, Zerifin, Israel
| | - Y. Morad
- Department of Ophthalmology, Assaf Harofeh Medical Center, Zerifin, Israel,Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Y. Goldich
- Department of Ophthalmology, Assaf Harofeh Medical Center, Zerifin, Israel
| | - V. Yahalom
- National Blood Group Reference Laboratory (NBGRL), Magen David Adom (MDA) – National Blood Services, Ramat Gan, Israel
| | - El. Pras
- Sheba Medical Center, Danek Gartener Institute of Human Genetics, Tel Hashomer, Israel,Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Er. Pras
- Department of Ophthalmology, Assaf Harofeh Medical Center, Zerifin, Israel,Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
37
|
Storry JR, Castilho L, Daniels G, Flegel WA, Garratty G, Francis CL, Moulds JM, Moulds JJ, Olsson ML, Poole J, Reid ME, Rouger P, van der Schoot E, Scott M, Smart E, Tani Y, Yu LC, Wendel S, Westhoff C, Yahalom V, Zelinski T. International Society of Blood Transfusion Working Party on red cell immunogenetics and blood group terminology: Berlin report. Vox Sang 2011; 101:77-82. [PMID: 21401621 DOI: 10.1111/j.1423-0410.2010.01462.x] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- J R Storry
- Clinical Immunology and Transfusion Medicine, University and Regional Laboratories, Lund, Sweden.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Shinar E, Etlin S, Frenkel O, Yahalom V. The implementation of rapid cooling and overnight hold of whole blood at ambient temperature before processing into components in Israel. Transfusion 2011; 51 Suppl 1:58S-64S. [DOI: 10.1111/j.1537-2995.2010.02964.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
39
|
Bartfeld G, Ellis M, Lubetzky A, Yahalom V, Kenet G. Storage of Blood Components Does Not Decrease Haemostatic Potential: In vitro Assessment of Fresh versus Stored Blood Components Using Thromboelastography. ACTA ACUST UNITED AC 2010; 37:329-335. [PMID: 21416027 DOI: 10.1159/000322256] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2010] [Accepted: 08/04/2010] [Indexed: 11/19/2022]
Abstract
SUMMARY: BACKGROUND: Major surgery and severe trauma typically lead to massive blood loss requiring rapid transfusion of large amounts of blood products. It has been suggested that fresh, unrefrigerated whole blood provides a haemostatic advantage in this setting. The aim of the current study was to compare the clot formation parameters of fresh, unrefrigerated whole blood and whole blood reconstituted from components stored for varying periods of time, using rotational thromboelastography (ROTEM®). METHODS: Fresh whole blood and reconstituted whole blood using combinations of non-leucoreduced red cell units (stored for 7, 14, 21, 28, or 35 days), platelet concentrates (stored for 1, 3 or 5 days), and fresh frozen plasma (stored for 6 months) were analysed using ROTEM. Measurements of the clotting time (CT), clot formation time (CFT), and maximal clot firmness (MCF) were compared between units of fresh whole blood and reconstituted whole blood samples. RESULTS: There was no difference in the haemostatic parameters measured of fresh whole blood and reconstituted whole blood using red cell units stored for less than 21 days. ROTEM demonstrated that the CT and CFT were significantly shorter for reconstituted whole blood samples using red cells stored for longer than 21 days when compared to fresh whole blood and to reconstituted whole blood samples using red cell units stored for less than 21 days. The CT was inversely correlated to the duration of platelet storage. The MCF was unchanged regardless of duration of blood product storage. CONCLUSION: Fresh unrefrigerated whole blood and blood products stored for short duration (less than 21 days) were not superior to those stored for longer durations.
Collapse
Affiliation(s)
- Galia Bartfeld
- Department of Internal Medicine B, Meir Medical Centre, Kfar Saba, Israel
| | | | | | | | | |
Collapse
|
40
|
Devine DV, Sher GD, Reesink HW, Panzer S, Hetzel PAS, Wong JK, Horvath M, Leitner GC, Schennach H, Nussbaumer W, Genoe K, Cioffi JM, Givisiez FN, Rogerson M, Howe D, Delage G, Sarappa C, Fu Y, Sarlija D, Vuk T, Strauss Patko M, Balija M, Jukić I, Ali A, Auvinen MK, Jaakonsalo E, Cazenave JP, Waller C, Kientz D, David B, Walther-Wenke G, Heiden M, Lin CK, Tsoi WC, Lee CK, Barotine-Toth K, Sawant RB, Murphy W, Quirke B, Bowler P, Shinar E, Yahalom V, Aprili G, Piccoli P, Gandini G, Tadokaro K, Nadarajan VS, de Kort W, Jansen N, Flanagan P, Forsberg PO, Hervig T, Letowska M, Lachert E, Dudziak K, Antoniewicz-Papis J, de Olim G, Nascimento F, Hindawi S, Teo D, Reddy R, Scholtz J, Swanevelder R, Rovira LP, Sauleda S, Carasa MAV, Vaquero MP, Ania MA, Gulliksson H, Holdsworth S, Cotton S, Howell C, Baldwin C, Cusick RM, Geele GA, Paden C, McEvoy P, Gottschall JL, McLaughlin LS, Benjamin RJ, Eder A, Draper NL, AuBuchon JP, León de González G. Inventory management. Vox Sang 2010; 98:e295-363. [PMID: 20432515 DOI: 10.1111/j.1423-0410.2009.01252.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
A critical aspect of blood transfusion is the timely provision of high quality blood products. This task remains a significant challenge for many blood services and blood systems reflecting the difficulty of balancing the recruitment of sufficient donors, the optimal utilization of the donor's gift, the increasing safety related restrictions on blood donation, a growing menu of specialized blood products and an ever-growing imperative to increase the efficiency of blood product provision from a cost perspective. As our industry now faces questions about our standard practices including whether or not the age of blood has a negative impact on recipients, it is timely to take a look at our collective inventory management practices. This International Forum represents an effort to get a snap shot of inventory management practices around the world, and to understand the range of different products provided for patients. In addition to sharing current inventory management practices, this Forum is intended to foster an exchange of ideas around where we see our field moving with respect to various issues including specialty products, new technologies, and reducing recipient risk from blood transfusion products.
Collapse
|
41
|
Stienlauf S, Yahalom V, Schwartz E, Shinar E, Segal G, Sidi Y. Epidemiology of human T-cell lymphotropic virus type 1 infection in blood donors, Israel. Emerg Infect Dis 2009; 15:1116-8. [PMID: 19624934 PMCID: PMC2744246 DOI: 10.3201/eid1507.080796] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
The prevalence of infection with human T-cell lymphotropic virus type 1 (HTLV-1) in blood donors from Israel is 1 infection/100,000 persons. In donors originating from Eastern Europe, the Middle East, and Latin America, prevalences are 7.7, 14.6, and 20.4, respectively. HTLV-1 prevalence may be high outside areas where HTLV-1 previously was known to be endemic.
Collapse
|
42
|
Sigler E, Shvidel L, Yahalom V, Berrebi A, Shtalrid M. Clinical significance of serologic markers related to red blood cell autoantibodies production after red blood cell transfusion-severe autoimmune hemolytic anemia occurring after transfusion and alloimmunization: successful treatment with rituximab. Transfusion 2009; 49:1370-4. [DOI: 10.1111/j.1537-2995.2009.02163.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
43
|
Anis E, Leventhal A, Slater PE, Shinar E, Yahalom V, Smetana Z, Zach R, Reznikovich S, Mendelson E, Danon Y, Lev B. Smallpox revaccination of 21000 first responders in Israel: lessons learned. Int J Infect Dis 2009; 13:403-9. [DOI: 10.1016/j.ijid.2008.08.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2007] [Revised: 07/31/2008] [Accepted: 08/06/2008] [Indexed: 11/29/2022] Open
|
44
|
Daniels G, Castilho L, Flegel WA, Fletcher A, Garratty G, Levene C, Lomas-Francis C, Moulds JM, Moulds JJ, Olsson ML, Overbeeke M, Poole J, Reid ME, Rouger P, van der Schoot E, Scott M, Sistonen P, Smart E, Storry JR, Tani Y, Yu LC, Wendel S, Westhoff C, Yahalom V, Zelinski T. International Society of Blood Transfusion Committee on terminology for red blood cell surface antigens: Macao report. Vox Sang 2009; 96:153-6. [PMID: 19152607 DOI: 10.1111/j.1423-0410.2008.01133.x] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- G Daniels
- Bristol Institute for Transfusion Sciences and The International Blood Group Reference Laboratory, NHS Blood and Transplant, Filton, Bristol, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Rottenberg Y, Yahalom V, Shinar E, Barchana M, Adler B, Paltiel O. Blood donors with positive direct antiglobulin tests are at increased risk for cancer. Transfusion 2009; 49:838-42. [PMID: 19170992 DOI: 10.1111/j.1537-2995.2008.02054.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Positive direct antiglobulin tests (DATs) have been associated with both autoimmunity and lymphoproliferative disorders. However, it is unknown whether DAT+ in healthy blood donors is associated with an increased risk of malignancies. STUDY DESIGN AND METHODS In the current study, all blood donors with DAT+ samples were identified during the years 1999 through 2003 through the Magen David Adom National Blood Services in Israel. This study compared the risk of cancer among 586 DAT+ and 2344 DAT- donors who were matched according to sex, age, and year of donation. The risk of cancer in DAT+ donors was also compared to expected rates in the general Israeli population. Cancer was ascertained through the Israel Cancer Registry. RESULTS Malignancies occurred among 17 (2.9%) of the DAT+ and 27 (1.2%) of the DAT- blood donors; of these, 3 donors in the DAT+ group were diagnosed with hematopoietic malignancies within 12 months of their donation. Even after excluding these early cases, the relative risk of developing cancer was 2.14 (95% confidence interval [CI], 1.13-4.10) comparing DAT+ with DAT- donors, while the relative risk for hematopoietic cancer was 8.3 (95% CI, 1.5-43.2). Comparing DAT+ blood donors with the general population, the standardized incidence ratios (observed/expected cases) were elevated at 2.11 (95% CI, 1.15-3.54; p = 0.16) for all malignancies and 8.03 (95% CI, 2.2-20.6; p = 0.003) for hematologic malignancies. CONCLUSION There is evidence of a significantly increased risk of cancer, especially hematologic malignancies, among blood donors with a positive DAT even within a short follow-up period.
Collapse
Affiliation(s)
- Yakir Rottenberg
- Department of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
| | | | | | | | | | | |
Collapse
|
46
|
Reesink HW, Engelfriet CP, Schennach H, Gassner C, Wendel S, Fontão-Wendel R, de Brito MA, Sistonen P, Matilainen J, Peyrard T, Pham BN, Rouger P, Le Pennec PY, Flegel WA, von Zabern I, Lin CK, Tsoi WC, Hoffer I, Barotine-Toth K, Joshi SR, Vasantha K, Yahalom V, Asher O, Levene C, Villa MA, Revelli N, Greppi N, Marconi M, Tani Y, Folman CC, de Haas M, Koopman MMW, Beckers E, Gounder DS, Flanagan P, Wall L, Aranburu Urtasun E, Hustinx H, Niederhauser C, Flickinger C, Nance SJ, Meny GM. Donors with a rare pheno (geno) type. Vox Sang 2008; 95:236-53. [PMID: 19121189 DOI: 10.1111/j.1423-0410.2008.01084.x] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
47
|
Novack L, Sarov B, Goldman-Levi R, Yahalom V, Safi J, Soliman H, Orgel M, Yaari A, Galai N, Pliskin J, Shinar E. Impact of pooling on accuracy of hepatitis B virus surface antigen screening of blood donations. Trans R Soc Trop Med Hyg 2008; 102:787-92. [DOI: 10.1016/j.trstmh.2008.04.005] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2007] [Revised: 04/03/2008] [Accepted: 04/03/2008] [Indexed: 12/27/2022] Open
|
48
|
Menashe I, Abaffy T, Hasin Y, Goshen S, Yahalom V, Luetje CW, Lancet D. Genetic elucidation of human hyperosmia to isovaleric acid. PLoS Biol 2008; 5:e284. [PMID: 17973576 PMCID: PMC2043052 DOI: 10.1371/journal.pbio.0050284] [Citation(s) in RCA: 153] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2007] [Accepted: 08/31/2007] [Indexed: 11/23/2022] Open
Abstract
The genetic basis of odorant-specific variations in human olfactory thresholds, and in particular of enhanced odorant sensitivity (hyperosmia), remains largely unknown. Olfactory receptor (OR) segregating pseudogenes, displaying both functional and nonfunctional alleles in humans, are excellent candidates to underlie these differences in olfactory sensitivity. To explore this hypothesis, we examined the association between olfactory detection threshold phenotypes of four odorants and segregating pseudogene genotypes of 43 ORs genome-wide. A strong association signal was observed between the single nucleotide polymorphism variants in OR11H7P and sensitivity to the odorant isovaleric acid. This association was largely due to the low frequency of homozygous pseudogenized genotype in individuals with specific hyperosmia to this odorant, implying a possible functional role of OR11H7P in isovaleric acid detection. This predicted receptor–ligand functional relationship was further verified using the Xenopus oocyte expression system, whereby the intact allele of OR11H7P exhibited a response to isovaleric acid. Notably, we also uncovered another mechanism affecting general olfactory acuity that manifested as a significant inter-odorant threshold concordance, resulting in an overrepresentation of individuals who were hyperosmic to several odorants. An involvement of polymorphisms in other downstream transduction genes is one possible explanation for this observation. Thus, human hyperosmia to isovaleric acid is a complex trait, contributed to by both receptor and other mechanisms in the olfactory signaling pathway. Humans can accurately discern thousands of odors, yet there is considerable inter-individual variation in the ability to detect different odors, with individuals exhibiting low sensitivity (hyposmia), high sensitivity (hyperosmia), or even “blindness” (anosmia) to particular odors. Such differences are thought to stem from genetic differences in olfactory receptor (OR) genes, which encode proteins that initiate olfactory signaling. OR segregating pseudogenes, which have both functional and inactive alleles in the population, are excellent candidates for producing this olfactory phenotype diversity. Here, we provide evidence that a particular segregating OR gene is related to sensitivity to a sweaty odorant, isovaleric acid. We show that hypersensitivity towards this odorant is seen predominantly in individuals who carry at least one copy of the intact allele. Furthermore, we demonstrate that this hyperosmia is a complex trait, being driven by additional factors affecting general olfactory acuity. Our results highlight a functional role of segregating pseudogenes in human olfactory variability, and constitute a step towards deciphering the genetic basis of human olfactory variability. Genetic epidemiology analysis reveals a multifaceted mechanism underlying enhanced olfactory sensitivity to the sweaty odor of isovaleric acid in humans.
Collapse
Affiliation(s)
- Idan Menashe
- Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel
- Crown Human Genome Center, Weizmann Institute of Science, Rehovot, Israel
| | - Tatjana Abaffy
- Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami, Florida, United States of America
| | - Yehudit Hasin
- Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel
- Crown Human Genome Center, Weizmann Institute of Science, Rehovot, Israel
| | - Sivan Goshen
- Department of Otolaryngology, Meir Hospital, Kfar Saba, Israel
| | - Vered Yahalom
- National Blood Group Reference Laboratory, Magen David Adom National Blood Services Center, Ramat-Gan, Israel
| | - Charles W Luetje
- Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami, Florida, United States of America
| | - Doron Lancet
- Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel
- Crown Human Genome Center, Weizmann Institute of Science, Rehovot, Israel
- * To whom correspondence should be addressed. E-mail:
| |
Collapse
|
49
|
Hue-Roye K, Lomas-Francis C, Belaygorod L, Lublin DM, Barnes J, Chung A, Fung-Kee-Fung K, Kinney J, Goldman-Lavi R, Yahalom V, Poole J, Ivankovic Z, Alcantara D, Bekavac M, Cepulic BG, Velliquette RW, Mason R, Reid ME. Three new high-prevalence antigens in the Cromer blood group system. Transfusion 2007; 47:1621-9. [PMID: 17725726 DOI: 10.1111/j.1537-2995.2007.01333.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND The Cromer blood group system consists of nine high-prevalence and three low-prevalence antigens carried on decay-accelerating factor (DAF). This report describes three new Cromer high-prevalence antigens, named ZENA, CROV, and CRAM. STUDY DESIGN AND METHODS Sequence analyses were performed on DNA from three probands whose serum samples each contained an alloantibody to a high-prevalence antigen in the Cromer blood group system. Polymerase chain reaction-restriction fragment length polymorphism analysis to detect the mutation encoding the CROV- phenotype was performed on 100 Croatian donors. To map the respective epitopes, DAF deletion mutants were tested by immunoblotting with eluates containing the antibodies. RESULTS In each proband, sequence analysis revealed a single-nucleotide substitution in DAF: ZENA, 726T>G mutation, predicted change His242Gln; CROV, 466G>A mutation, predicted change Glu156Lys; and CRAM, 740A>G mutation, predicted change Gln247Arg. By analysis of DAF deletion mutants, the CROV antigenic determinant mapped to the complement control protein (CCP) domain 2, which is encoded by exon 3, whereas ZENA and CRAM mapped to CCP4, which is encoded by exon 6. CONCLUSION This study describes three novel high-prevalence antigens in the Cromer blood group system each characterized by a predicted single-amino-acid substitution. The antigens have been assigned the following International Society of Blood Transfusion (ISBT) numbers: ZENA is CROM13, CROV is CROM14, and CRAM is CROM15.
Collapse
Affiliation(s)
- Kim Hue-Roye
- Laboratory of Immunochemistry and the Laboratory of Immunohematology, New York Blood Center, New York, New York, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Sarov B, Novack L, Galai N, Yaari A, Orgel M, Safi J, Yahalom V, Shinar E. Estimation of delay in detecting hepatitis C virus antibodies in pools compared to individual testing on seroconversion panels. Clin Microbiol Infect 2007; 13:737-9. [PMID: 17441976 DOI: 10.1111/j.1469-0691.2007.01740.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Testing for anti-hepatitis C virus (HCV) antibodies in pools may reduce blood screening costs, making this approach affordable for developing countries, provided that the dilution of infected blood does not significantly increase the number of undetectable viral particles, especially in seroconverters. This study assessed the delay in detection of HCV antibodies in five HCV seroconversion panels, tested in pools of 6-48 samples, and estimated the risk of transfusion-transmitted HCV caused by pooling. The delay in detection of positive samples was 5-12 days for pools of all sizes, adding 7% to the risk of HCV transmission that occurs when blood donors' samples are tested individually.
Collapse
Affiliation(s)
- B Sarov
- Department of Epidemiology and Health Services Evaluation, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
| | | | | | | | | | | | | | | |
Collapse
|